UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
   
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 20092010
OR
   
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-11250
DIONEX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
   
Delaware 94-2647429
   
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
   
1228 Titan Way, Sunnyvale, California 94085
   
(Address of principal executive offices) (Zip Code)
(408) 737-0700
(Registrant’s Telephone Number, including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YESþ   NOo
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YESoþ   NOo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
       
Large accelerated filerþ Accelerated filero Non-accelerated filero
Smaller reporting companyo
(Do not check if a smaller reporting company)Smaller reporting companyo
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YESo   NOþ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of November 5, 2009:4, 2010:
   
CLASS NUMBER OF SHARES
   
Common Stock 17,723,10617,421,071
 
 

 


 

DIONEX CORPORATION
INDEX
     
  Page (s)
  3 
  3 
  3 
  4 
  5 
  6 
  16 
  1920 
  2021
 
  22 
  2022 
  2325 
  2527 
  2728 
 Exhibit 31.1EX-31.1
 Exhibit 31.2EX-31.2
 Exhibit 32.1EX-32.1
 Exhibit 32.2EX-32.2
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT

2


Part I. Financial Information
Item 1. Financial Statements
DIONEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
                
 September 30, June 30,  September 30, June 30, 
 2009 2009  2010 2010 
ASSETS  
Current assets:  
Cash and cash equivalents $78,234 $69,684  $76,852 $69,830 
Short-term investments 460 641  176 448 
Accounts receivable (net of allowance for doubtful accounts of $443 at September 30, 2009 and $560 at June 30, 2009) 70,267 70,535 
Accounts receivable (net of allowance for doubtful accounts of $524 and $543 as of September 30, 2010 and June 30, 2010, respectively) 86,752 86,780 
Inventories 37,679 31,274  41,562 37,458 
Deferred taxes 12,255 12,171  14,001 14,036 
Prepaid expenses and other current assets 18,957 21,917  21,576 18,991 
          
Total current assets 217,852 206,222  240,919 227,543 
Property, plant and equipment, net 78,312 71,927  80,623 76,062 
Goodwill 36,375 29,354  35,913 35,013 
Intangible assets, net 15,548 8,506  17,654 13,859 
Other assets 13,891 13,975  10,213 9,511 
          
 $361,978 $329,984  $385,322 $361,988 
          
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Notes payable $15,137 $64 
Borrowings under line of credit $17,371 $3,149 
Accounts payable 18,003 16,545  14,633 17,303 
Accrued liabilities 31,203 31,222  32,993 33,980 
Deferred revenue 24,246 22,559  25,985 25,203 
Income taxes payable 9,101 4,581  3,605 5,247 
Accrued product warranty 2,987 3,028  2,617 2,532 
          
Total current liabilities 100,677 77,999  97,204 87,414 
Deferred and other income taxes payable 25,627 24,348  19,160 16,427 
Other long-term liabilities 3,685 3,707  7,616 7,272 
Commitments and other contingencies (Note 13) 
Commitments and other contingencies (Note 12) 
Stockholders’ equity:  
Dionex Corporation stockholders’ equity  
Preferred stock (par value $.001 per share; 1,000,000 shares authorized; none outstanding)      
Common stock (par value $.001 per share; 80,000,000 shares authorized; issued and outstanding:  
17,647,678 shares at September 30, 2009 and 17,759,690 shares at June 30, 2009) 189,674 186,649 
17,301,892 shares as of September 30, 2010 and 17,437,276 shares as of June 30, 2010) and capital in excess of par value 210,507 207,855 
Retained earnings 22,385 21,459  33,435 34,195 
Accumulated other comprehensive income 18,268 14,306  15,128 6,733 
          
Total Dionex Corporation stockholders’ equity 230,327 222,414  259,070 248,783 
Noncontrolling interest 1,662 1,516 
Noncontrolling interests 2,272 2,092 
          
Total stockholders’ equity 231,989 223,930  261,342 250,875 
          
 $361,978 $329,984  $385,322 $361,988 
          
See notes to condensed consolidated financial statements.

3


DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited)
                
 Three Months Ended  Three Months Ended 
 September 30,  September 30, 
 2009 2008  2010 2009 
Net sales $90,664 $93,435  $102,874 $90,664 
Cost of sales 31,041 30,724  36,472 31,041 
          
Gross profit 59,623 62,711  66,402 59,623 
          
Operating expenses:  
Selling, general and administrative 35,983 36,197  40,266 35,983 
Research and product development 7,172 7,029  8,013 7,172 
          
Total operating expenses 43,155 43,226  48,279 43,155 
          
Operating income 16,468 19,485  18,123 16,468 
Interest income 83 403  60 83 
Interest expense  (36)  (218)  (33)  (36)
Other income (expense), net 40  (403)  (1,038) 40 
          
Income before taxes 16,555 19,267  17,112 16,555 
Taxes on income 5,969 7,241  5,790 5,969 
          
Net income 10,586 12,026  11,322 10,586 
Less: Net income attributable to noncontrolling interest 250 210 
Less: Net income attributable to noncontrolling interests 361 250 
          
Net income attributable to Dionex Corporation $10,336 $11,816  $10,961 $10,336 
          
  
Basic earnings per share attributable to Dionex Corporation $0.58 $0.65  $0.63 $0.58 
          
Diluted earnings per share attributable to Dionex Corporation $0.57 $0.64  $0.62 $0.57 
          
Shares used in computing per share amounts:  
Basic 17,712 18,068  17,388 17,712 
Diluted 18,050 18,547  17,698 18,050 
See notes to condensed consolidated financial statements.

4


DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
                
 Three Months Ended  Three Months Ended 
 September 30,  September 30, 
 2009 2008  2010 2009 
Cash flows from operating activities:  
Net income $10,586 $12,026  $11,322 $10,586 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization 2,478 2,320  3,380 2,478 
Stock-based compensation 1,578 1,485  1,972 1,578 
Provision (benefit) for bad debts  (155) 43 
Bad debt recoveries  (114)  (155)
Loss on disposal of fixed assets 29 34  341 29 
Tax benefit related to stock transactions  (165)  (111)  (337)  (165)
Deferred income taxes  (5)  (85) 89  (5)
Changes in assets and liabilities, net of acquired assets and assumed liabilities:  
Accounts receivable 2,435 978  4,500 2,435 
Inventories  (1,656)  (3,960)  (734)  (1,656)
Prepaid expenses and other assets 753 578 
Prepaid expenses and other current assets  (543) 753 
Prepaid income taxes 2,521 13   (1,756) 2,521 
Accounts payable 783 110   (2,854) 783 
Accrued liabilities  (1,685)  (3,360)  (3,186)  (1,685)
Deferred revenue 1,101 76   (317) 1,101 
Income taxes payable 4,457  (1,476)  (1,214) 4,457 
Accrued product warranty  (173) 10   (59)  (173)
          
Net cash provided by operating activities 22,882 8,681  10,490 22,882 
          
Cash flows from investing activities:  
Purchase of marketable securities   (2,713)
Proceeds from sale of marketable securities 232   288 232 
Purchase of property, plant and equipment  (2,751)  (4,581)  (5,178)  (2,751)
Purchase of business  (21,100)  (952)
Purchase of intangible assets  (4,512)  (21,100)
          
Net cash used for investing activities  (23,619)  (8,246)  (9,402)  (23,619)
          
Cash flows from financing activities:  
Net change in notes payable 15,075 3,265 
Net borrowings under line-of-credit 14,222 15,075 
Proceeds from issuance of common stock 3,261 1,657  2,577 3,261 
Tax benefit related to stock transactions 165 111  337 165 
Repurchase of common stock  (11,175)  (13,332)  (13,952)  (11,175)
Dividends paid to noncontrolling interests  (104)     (104)
          
Net cash provided by (used for) financing activities 7,222  (8,299)
Net cash provided by financing activities 3,184 7,222 
          
Effect of exchange rate changes on cash 2,065  (4,712) 2,750 2,065 
          
Net increase (decrease) in cash and cash equivalents 8,550  (12,576)
Net increase in cash and cash equivalents 7,022 8,550 
Cash and cash equivalents, beginning of period 69,684 75,624  69,830 69,684 
          
Cash and cash equivalents, end of period $78,234 $63,048  $76,852 $78,234 
          
Supplemental disclosures of cash flow information:  
Income taxes paid $1,803 $8,325  $8,907 $1,803 
Interest expense paid 28 202  28 28 
Supplemental schedule of non-cash investing and financing activities:  
Accrued purchases of property, plant and equipment 588 526  106 588 
Accrued consideration of business purchase  592 
Elimination of equity interest associated with step-acquisition of business  760 
See notes to condensed consolidated financial statements

5


DIONEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1.Note 1: Summary of Significant Accounting Policies
Organization and Basis of Presentation
The condensed consolidated financial statements included herein have been prepared by Dionex Corporation, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2009.2010. Unless the context otherwise requires, the terms “Dionex,” “we,” “our” and “us” and words of similar import as used in these notes to condensed consolidated financial statements include Dionex Corporation and its consolidated subsidiaries.
The unaudited condensed consolidated financial statements included herein reflect all adjustments (which include only normal, recurring adjustments) that are, in the opinion of management, necessary to state fairly the results for the periods presented. The results for such periods are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2010. Separate line item2011.
New Accounting Standards Adopted
Transfers of Financial Assets
In June 2009, the Financial Accounting Standards Board (“FASB”) issued new standards for the accounting for transfers of financial assets. These new standards amend the criteria for a transfer of a financial assets to be accounted for as a sale, establish more stringent conditions for reporting a transfer of a portion of a financial asset as a sale, change the initial measurement of a transferor’s interest in transferred financial assets, eliminate the qualifying special-purpose entity concept and require enhanced disclosures. Dionex adopted these standards in the first quarter of fiscal 2011 and they did not have a material impact on our consolidated financial statements but did expand our disclosures about transfers of financial assets. Refer to Note 7 for additional information.
Financial Instruments
In January 2010, the FASB issued a new accounting standard to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 and Level 2 of the change in prepaid income taxes has been providedfair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a roll forward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). The guidance became effective for us with the reporting period beginning January 1, 2010, except for the disclosure on the roll forward activities for Level 3 fair value measurements, which is effective for us in the condensed consolidated statementfirst quarter of cash flows forfiscal 2011. Other than requiring additional disclosures, adoption of this new standard did not have a material impact on our financial statements or any additional disclosures as Dionex did not have any financial instruments transfers between Level 1 and 2 during the three months ended September 30, 20082010.
Revenue Recognition
Net sales are derived primarily from sales of products, software licenses, and services (including installation, training, other consulting services, and extended maintenance contracts on our products). The following revenue recognition policies define the manner in which Dionex accounts for sales transactions.
Dionex recognizes revenue when persuasive evidence of an arrangement exists, the product has been delivered or service has been performed, the sales price is fixed or determinable, and collection is reasonably assured. Delivery of the product is generally considered to conformhave occurred when shipped. Shipping charges billed to customers are included in net sales, and the fiscal 2010 presentation. Net operating resultsrelated costs are included in cost of sales. Sales from products are typically not subject to rights of return and, historically, actual sales returns have not been affected by this re-classification.
2. New Accounting Pronouncements
In May 2009,significant. Dionex sells products through its direct sales force and through distributors and resellers. Sales through distributors and resellers are recognized as revenue upon sale to the Financial Accounting Standards Board (FASB) issued an Accounting Standard Update related to subsequent events. This accounting standard is intended to establish general standards of the accounting for and disclosures of events that occur after the balance sheet date but before financial statementsdistributor or reseller as these sales are issued or are availableconsidered to be issued. It requires the disclosurefinal and no right of the date through which an entity has evaluated subsequent events and the basis for selecting that date, that is, whether that date represents the date the financial statements were issuedreturn or were available to be issued. The accounting standard is effective for interim or annual financial periods ending after June 15, 2009 and was adopted by us during the quarter ended June 30, 2009. Additional disclosures are provided in Note 17.
In April 2009, the FASB issued an Accounting Standard Update related to the accounting for assets acquired and liabilities assumed in a business combination that arise from contingencies, which amends the business combination accounting standard to require contingent assets acquired and liabilities assumed to be recognized at fair value on the acquisition date if fair value can be reasonably estimated during the measurement period. If fair value cannot be reasonably estimated during the measurement period, the contingent asset or liability would be recognized in accordance with the accounting standard related to contingencies and the estimation of the amount of a loss. Further, this eliminated the specific subsequent accounting guidance for contingent assets and liabilities from the application of the business combination accounting standard. However, contingent consideration arrangements of an acquiree assumed by the acquirer in a business combination would still be initially and subsequently measured at fair value. This accounting guidance is effective for all business acquisitions occurring on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, which began on July 1, 2009 for us. Effective July 1, 2009, we adopted the accounting standard related to assets acquired and liabilities assumed in a business combinations.
In April 2009, the FASB issued two Accounting Standard Updates related to disclosures about the fair value of financial instruments in interim period financial statements of publicly traded companies and in summarized financial information required by another Accounting Standard Update. These updates are effective for interim and annual reporting periods ending after June 15, 2009. Effective July 1, 2009, we adopted the accounting guidance related to the fair value disclosure of financial instruments.
In April 2009, the FASB issued two Accounting Standard Updates related to the recognition and presentation of other-than-temporary impairments (“OTTI”), which provides operational guidance for determining OTTI for debt securities. These updates are effective for interim and annual periods ending after June 15, 2009. Effective July 1, 2009, we adopted the accounting guidance related to the recognition and presentation of OTTI. The adoption of this accounting guidance did not have an impact on our condensed consolidated financial statements.
In December 2007, the FASB issued an Accounting Standard Update related to noncontrolling interests in subsidiaries to establishprice protection exists.

6


accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary, whichCustomer acceptance is sometimes referredgenerally limited to as a minority interest, is a third-party ownership interest in the consolidated entity that should be reported as a component of equity in the condensed consolidated financial statements. Among other requirements, the new guidance requires the consolidated statement of income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest. The new guidance also requires disclosure on the face of the consolidated statement of income of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. This accounting standard is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Effective July 1, 2009, we adopted the accounting standard related to noncontrolling interests in subsidiaries. In addition, the presentation and disclosure requirements of the Accounting Standard Update have been applied retrospectively toperformance under our condensed consolidated balance sheet as of June 30, 2009, our condensed consolidated statements of income and cash flows, and our comprehensive income disclosure in Note 7 for the three months ended September 30, 2008.
In December 2007, the FASB issued a revision to a previous Accounting Standard Update related to business combinations. The revised accounting standard expands the definition of a business combination and requires the fair value of the purchase price of an acquisition, including the issuance of equity securities, to be determined on the acquisition date. It also requires thatpublished product specifications. When additional customer acceptance conditions apply, all assets, liabilities, contingent consideration and contingencies of an acquired business be recorded at fair value at the acquisition date. In addition, the revised accounting standard now requires that acquisition costs generally be expensed as incurred, restructuring costs generally be expensed in periods subsequent to the acquisition date, and changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period that impacts income tax expense. The effect of this revision applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008 with early adoption prohibited, which began on July 1, 2009 for us. Effective July 1, 2009, we adopted the revised accounting standard related to business combinations.
In April 2008, the FASB released an Accounting Standard Update to determine the useful life of intangible assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under the previously issued standard on goodwill and other intangible assets. The intent of the statement is to improve the consistency between the useful life of a recognized intangible asset under the accounting standard and the period of expected cash flows used to measure the fair value of the asset under the accounting standard for business combinations and other U.S. generally accepted accounting principles. Effective July 1, 2009, we adopted the accounting guidancerevenue related to the useful life of certain intangible assets. The adoption did not have an impact on our condensed consolidated financial statements.
In March 2008, the FASB issued an Accounting Standard Update related to disclosures about derivative instruments and hedging activities. The accounting standard enhances financial disclosure by requiring that objectives for using derivative instruments be described in terms of underlying risk and accounting designation in the form of tabular presentation, requiring transparency with respect to the entity’s liquidity from using derivatives, and cross-referencing an entity’s derivative information within its financial footnotes. Effective July 1, 2009, we adopted the accounting standard related to the disclosures about derivative instruments and hedging activities.
In February 2007, the FASB issued an Accounting Standard Update related to the fair value option for financial assets and financial liabilities. It permits entities to choose, at specified election dates, to measure eligible items at fair value (or “fair value option”) and to report in earnings unrealized gains and losses on those items for which the fair value option has been elected. The standard also requires entities to display the fair value of those assets and liabilities on the face of the balance sheet and establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. The accounting standard was effective for us as of the first quarter of fiscal 2009. Currently, we have elected not to adopt the fair value option under this update.sale is deferred until acceptance is obtained.
In October 2009, the FASB issued an Accounting Standard Updatea new accounting standard for multiple deliverable revenue arrangements. The new standard changes the requirements for establishing separate units of accounting in a multiple element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price. The FASB also issued a new accounting standard for certain revenue arrangements that include software elements. This new standard excludes software that is contained on a tangible product from the scope of software revenue guidance if the software is essential to the tangible product’s functionality. Dionex prospectively adopted both these standards in the first quarter of fiscal 2011 for new and materially modified arrangements originating after July 1, 2010. The impact of adopting these standards was not material to net sales on our condensed consolidated financial statements for the three-months ended September 30, 2010. The new accounting standard for revenue recognition withif applied in the same manner to the year ended June 30, 2010 would not have had a material impact on net sales or to our consolidated financial statements for that fiscal year. Dionex anticipates the effect of the adoption of these standards in future periods will primarily depend upon the nature and volume of new or materially modified arrangements.
Under these new standards, when a sales arrangement contains multiple deliverables. This guidance eliminates the residual method under the current guidance and replaces it with the “relative selling price” method when allocatingelements, such as products, software licenses and/or services, Dionex allocates revenue into each element based on a multiple deliverable arrangement. The selling price forhierarchy. Using the selling price hierarchy, Dionex determines selling price of each deliverable shall be determined using vendor specific objective evidence (“VSOE”), if it exists, and otherwise third-party evidence (“TPE”). If neither VSOE nor TPE of selling price exists, Dionex uses estimated selling price (“ESP”). Dionex generally expects that it will not be able to establish TPE due to the nature of the markets in which we compete, and, as such, Dionex typically will determine selling price using VSOE or if it exists, otherwise third-party evidencenot available, ESP.
Dionex’s basis for establishing VSOE of a deliverable’s selling price. If neither exists forprice consists of standalone sales transactions when the same or similar product or service is sold separately. However, when services are never sold separately, such as product installation services, VSOE is based on the product’s estimated installation hours based on historical experience multiplied by the standard service billing rate. In determining VSOE, Dionex requires that a deliverable, the vendor shall use its best estimatesubstantial majority of the selling price for that deliverable. After adoption, this guidance willa product or service fall within a reasonably narrow price or hour range, as defined by Dionex. Dionex also require expanded qualitativeconsiders the geographies in which the products or services are sold, major product and quantitative disclosures. This accounting guidance is effective for revenue arrangements entered into or materially modifiedservice groups, and other environmental variables in fiscal years beginning on or after June 15, 2010, although early adoption is permitted. We are currentlydetermining VSOE. Absent the existence of VSOE and TPE, our determination of a deliverable’s ESP involves evaluating the potential impact, if any, of the adoption of the accounting guidance on our consolidated financial position, results of operations and cash flow.

7


3. Stock-Based Compensation
We account for our stock plans by measuring the cost of employee services received in exchange for an award of equity instrumentsseveral factors based on the grant date fair valuespecific facts and circumstances of these arrangements, which include pricing strategy and policies driven by geographies, market conditions, competitive landscape, correlation between proportionate selling price and list price established by management having the award. We have a stock-based compensation plan (“Equity Incentive Plan”)relevant authority, and an employee stock purchase plan (“ESPP”). Pursuant toother environmental variables in which the Equity Incentive Plan, we issue stock optionsdeliverable is sold.
For multiple element arrangements which include extended maintenance contracts, Dionex allocates and restricted stock units.
Generally, stock options granted to employees and non-employee directors fully vest four years fromdefers the grant date and have a termamount of ten years. We recognize stock-based compensation expense over the requisite service period of the individual grants, generally,consideration equal to the vesting period.
Stock option activity under our Equity Incentive Plan during the three months ended September 30, 2009 was as follows:
                 
          Weighted    
          Average    
      Weighted  Remaining  Aggregate 
      Average  Contractual  Intrinsic 
  Options  Exercise  Term  Value 
  Outstanding  Price  (Years)  (in 000’s ) 
Balance at June 30, 2009  1,699,640  $53.02         
Options granted    $         
Options exercised  (52,105) $42.23         
Options forfeited/canceled/expired  (13,375) $69.48         
               
Balance at September 30, 2009  1,634,160  $53.23   5.97  $23,373 
               
Options vested and expected to vest at September 30, 2009  1,625,535  $53.17   5.95  $23,329 
               
Exercisable at September 30, 2009  1,150,427  $47.89   4.96  $21,282 
               
The aggregate intrinsic values in the table above represent the total pretax intrinsic values based on our closing stockseparately stated price of $64.97 at September 30, 2009, which would have been received by the option holders had all option holders exercised their options as of that date.
The total pre-tax intrinsic value of options exercised during the three months ended September 30, 2009 was $2.2 million.
Under our ESPP, eligible employees are permitted to have salary withholdings to purchase shares of common stock at a price equal to 85% of the lower of the market value of the stock at the beginning or end of each six-month offer period, subject to certain annual limitations.
Our stock-based compensation expense for the three ended September 30, 2009 and 2008 was as follows (in thousands):
         
  Three Months Ended 
  September 30, 
  2009  2008 
Cost of sales $158  $185 
Selling, general and administrative expenses  1,041   864 
Research and development expenses  379   436 
       
Total stock-based compensation expenses  1,578   1,485 
Tax effect on stock-based compensation  (506)  (487)
       
Net effect on net income $1,331  $998 
       

8


The fair value of each option on the date of grant was estimated using the Black-Scholes-Merton option-pricing model using a single option approach for options granted after June 30, 2005, with the following weighted-average assumptions:
         
  Three Months Ended
  September 30,
  2009 2008
Volatility for Equity Incentive Plan     29%
Volatility for ESPP  36%  24%
Risk-free interest rate for Equity Incentive Plan     3.3%
Risk-free interest rate for ESPP  0.3%  2.0%
Expected life of Equity Incentive Plan    4.70 years
Expected life of ESPP 6 months 6 months
Expected dividend $0.00  $0.00 
As of September 30, 2009, the unrecorded deferred stock-based compensation balance related to stock options was $9.6 million after estimated forfeitures and will be recognized over an estimated weighted average amortization period of 2.4 years. We did not issue any options under the Equity Incentive Plan during the first quarter of fiscal 2010.
Determining Fair Value
Valuation and amortization method — We estimate the fair value of stock options granted using the Black-Scholes-Merton option pricing formula and a single option award approach. This fair value is then amortizedrecognizes revenue on a straight-line basis over the requisite service periods ofcontract period.
For multiple element arrangements which contain software deliverables and non-software deliverables (i.e. instruments) where the awards, whichinstruments’ essential functionality is generally the vesting period.
Expected Term — The expected term represents the period that our stock-based awards are expected to be outstanding and was determined basednot dependent on historical experience of similar awards, giving considerationboth deliverables functioning together, revenue is allocated to the contractual termssoftware deliverables as a group using the relative selling prices of the stock-based awards, vesting schedules and expectations of future employee behavior as influenced by changes to the terms of our stock-based awards.
Expected Volatility — Our computation of expected volatility for the three months ended September 30, 2009 and 2008 is based on a combination of historical and market-based implied volatility.
Risk-Free Interest Rate — The risk-free interest rate usedeach deliverable in the Black-Scholes-Merton valuation method isarrangement based on the implied yield currently available on U.S. Treasury zero-coupon issuesselling price hierarchy. The consideration allocated to the software deliverable group is then allocated to each software deliverable within that group in accordance with an equivalent remaining term.software revenue recognition guidance.
Expected Dividend — The expected dividend assumption is based on our current expectations about our anticipated dividend policy.
4. Inventories
Inventories consistedFor perpetual software licenses, Dionex recognizes revenue at the inception of (in thousands):
         
  September 30,  June 30, 
  2009  2009 
Finished goods $23,817  $19,070 
Work in process  1,564   1,119 
Raw materials  12,298   11,085 
       
  $37,679  $31,274 
       

9


5. Property, Plant and Equipment, Net
Property, Plant and Equipment, Net consistedthe license term assuming all revenue recognition criteria have been met. Dionex uses the residual method to allocate revenue to software licenses at the inception of (in thousands):
         
  September 30,  June 30, 
  2009  2009 
Land $28,141  $24,533 
Buildings and improvements  48,298   47,060 
Machinery, equipment and tooling  42,872   40,960 
Furniture and fixtures  11,450   10,884 
Construction-in-progress  3,897   2,408 
       
   134,658   125,845 
Accumulated depreciation and amortization  (56,346)  (53,918)
       
Property, plant and equipment, net $78,312  $71,927 
       
6. Short-term Investments
Short-term investments are recorded at their fair value. The difference between the license term when VSOE of fair value for the undelivered elements exists, such as software installations, and amortized costall other revenue recognition criteria have been satisfied. If Dionex cannot objectively determine the VSOE of short-term investments classified as “available-for-sale” securitiesfair value of any undelivered elements included in these multiple-element arrangements, revenue is recorded in other comprehensive income, netdeferred until all elements are delivered, or until VSOE of deferred taxes. We do not hold any auction-rate securities. As of September 30, 2009, short-term investments included an equity indexed derivative totaling $452,000.fair value can be objectively determined for the remaining undelivered elements.
The aggregate market value, cost basis, and gross unrealized gains and losses of short-term investments classified as “available-for-sale” securities were as follows (in thousands):
                     
      Gross  
      Unrealized Fair
  Cost Losses Value
September 30, 2009, Certificate of deposits $8  $  $8 
June 30, 2009, Certificate of deposits $8  $  $8 
7. Comprehensive Income
Comprehensive income is the change in stockholders’ equity arising from transactions other than investments by owners and distributions to owners. The significant component of comprehensive income, other than net income, is the foreign currency translation adjustments. The components of comprehensive income attributable to Dionex Corporation were as follows (in thousands):
         
  Three Months Ended 
  September 30, 
  2009  2008 
Net income, as reported $10,336  $11,816 
Foreign currency translation adjustments, net of taxes  4,862   (10,201)
Unrealized loss on net investment hedge  (901)  (110)
Unrealized gain on securities available for sale, net of taxes  1    
       
Comprehensive income  14,298   1,505 
Comprehensive income (loss) attributable to the noncontrolling interests  250   210 
Dividend attributable to noncontrolling interests  (319)  (459)
       
Comprehensive income attributable to Dionex Corporation $14,229  $1,256 
       
8. Common Stock Repurchases
During the three months ended September 30, 2009, we repurchased 188,253 shares of our common stock on the open market for approximately $11.2 million (at an average repurchase price of $59.36 per share), compared with 201,584 shares repurchased for approximately $13.3 million (at an average repurchase price of $66.14 per share) in the same period of the prior fiscal year.
9.Note 2: Earnings perPer Share
Basic earnings per share attributable to Dionex Corporation are determined by dividing net income attributable to Dionex Corporation by the weighted average number of

10


common shares outstanding during the period. Diluted earnings per share attributable to Dionex Corporation are determined by dividing net income attributable to Dionex Corporation by the weighted average number of common shares used in the basic earnings per share calculation, plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding under the treasury stock method.

7


The following table is a reconciliation of the numerators and denominators used in computing basic and diluted earnings per share attributable to Dionex Corporation (in thousands, except per share data):
                
 Three Months Ended  Three Months Ended 
 September 30,  September 30, 
 2009 2008  2010 2009 
Numerator:  
Net income attributable to Dionex Corporation $10,336 $11,816  $10,961 $10,336 
Denominator:  
Weighted average shares used to compute net income per common share — basic 17,712 18,068 
Weighted average shares used to compute earnings per share attribution to Dionex Corporation — basic 17,388 17,712 
Effect of dilutive stock options 338 479  310 338 
          
Weighted average shares used to compute net income per common share — diluted 18,050 18,547 
Weighted average shares used to compute earnings per share attribution to Dionex Corporation— diluted 17,698 18,050 
          
Basic earnings per share attributable to Dionex Corporation $0.58 $0.65  $0.63 $0.58 
          
Diluted earnings per share attributable to Dionex Corporation $0.57 $0.64  $0.62 $0.57 
          
 
Antidilutive common equivalent shares related to stock awards are excluded from the calculation of diluted earnings per share attribution to Dionex Corporation 594 622 
Antidilutive common equivalent shares related to stock options are excluded fromNote 3: Fair Value Measurements
In accordance with the calculation of diluted shares. Approximately 622,493accounting standards for fair value measurements and 455,710 shares were excluded at September 30, 2009 and 2008, respectively because they were antidilutive.
10. Acquisition
On September 22, 2009, we entered into a purchase agreement with ESA Biosciences, Inc. to acquire certaindisclosures, assets and liabilities are measured at fair value on a recurring basis as of its Life Science Tools (“LST”)the end of each reporting period. Dionex applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and Laboratory Services business divisions. The acquisition increased our portfoliobases the categorization within the hierarchy upon the lowest level of High Performance Liquid Chromatography (“HPLC”) solutionsinput that is available and expanded our presence in the life sciences market, particularly in clinical research applications. The purchase consideration totaled $21.6 million, consisting of $21.1 million in cash and $486,000 in assumed liabilities. The purchase price has been preliminarily allocated to assets and liabilities acquired based upon our estimate of their fair values. Through the date that we finalize our purchase price allocation, any changessignificant to the preliminary fair value estimates will be reflected in goodwill. The acquired goodwill is deductible for tax purposes and it reflects the value that is attributable primarily to operating synergy benefits unique to us. The impact on our result of operations as a result of this acquisition for the quarter and since the acquisition is immaterial to our condensed consolidated financial statements..measurement:
Level 1 input utilize observable data such as quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs utilize data points other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.
Level 3 inputs utilize unobservable data points for the asset of liability in which there is little or no market data, which require the reporting entity to develop its own assumptions.
The following table summarizes theour assets and liabilities measured at fair value of the assets acquired and liabilities assumed at the date of acquisition (in thousands):
     
Accounts receivable and prepaid assets $110 
Inventory  3,190 
Other assets  26 
Property, plant, equipment  3,986 
Identifiable intangible assets  7,290 
Goodwill  6,984 
    
Total assets acquired  21,586 
Accounts payable and accrued liabilities  (197)
Deferred revenue  (254)
Warranty obligations  (35)
    
Total liabilities assumed  (486)
    
Total purchase price, net of liabilities assumed $21,100 
    
Acquisition related costs totaling approximately $350,000 were charged to selling, general and administrative expense for the three months ended September 30, 2009.
11. Goodwill and Other Intangible Assets
Information regarding our goodwill and other intangible assets reflects current foreign exchange rates.

11


The change in the carrying amount of goodwill for the three months ended September 30, 2009 was as follows (in thousands):
     
  Total 
Balance as of July 1, 2009 $29,354 
Translation adjustments  443 
Additions  6,578 
    
Balance as of September 30, 2009 $36,375 
    
Our reporting units consist of our operating segments, the Chemical Analysis Business Unit (CABU) and the Life Sciences Business Unit (LSBU). Except for goodwill associated with the AutoTrace acquisition that was assigned to the CABU reporting unit, all goodwill has been assigned to the LSBU reporting unit. The evaluation of goodwill is based upon the fair value of this reporting unit. We performed annual impairment tests on goodwill in April 2009 and determined that goodwill was not impaired. Additionally, there was no occurrence of events indicating a possible impairment of recorded goodwillrecurring basis as of September 30, 2009.2010:
Information regarding our other intangible assets follows (in thousands):
                         
  As of September 30, 2009  As of June 30, 2009 
  Carrying  Accumulated      Carrying  Accumulated    
  Amount  Amortization  Net  Amount  Amortization  Net 
Patents and trademarks $5,958  $(2,129) $3,829  $7,088  $(1,978) $5,110 
Developed technology  15,738   (10,613)  5,125   11,054   (10,327)  1,177 
Tradenames  2,830      2,830          
Customer lists  5,121   (1,357)  3,764   3,391   (1,172)  2,219 
                   
Total $29,647  $(14,099) $15,548  $21,983  $(13,477) $8,506 
                   
Except for the amount allocated to acquired tradenames, which was $2.8 million as of September 30, 2009 and is not amortizable, we amortize patents and trademarks over a period of seven to sixteen years and the remaining weighted average amortization period for this category is approximately eleven years.
We amortize developed technology over a period of seven years based on experiences from our historical product cycles.
We amortize customer lists over a period of two to ten years and the remaining weighted average amortization period for this category is approximately seven years.
Amortization expense related to intangible assets was $331,553 and $284,479 for the three months ended September 30, 2009 and 2008, respectively. The remaining estimated amortization for each of the five fiscal years subsequent to September 30, 2009 is as follows (in thousands):
     
  Remaining 
  Amortization 
  Expense 
2010 (remaining nine months) $1,984 
2011  2,681 
2012  2,407 
2013  1,727 
2014  1,217 
Thereafter  2,702 
    
Total $12,718 
    
12. Warranty
Product warranties are recorded at the time revenue is recognized for certain product shipments. Warranty expense is affected by product failure rates, material usage and service costs incurred in correcting a product failure. Should actual product failure rates, material usage or service costs differ from our estimates, revisions to the warranty liability would be required.

12


Details of the change in accrued product warranty for the three months ended September, 2009 and 2008 were as follows (in thousands):
                     
              Actual  
  Balance Provision Other Warranty Balance
  Beginning For Adjustments Costs End of
  Of Period Warranties Accounts (1) Incurred Period
Accrued Product Warranty                    
Three Months Ended:                    
September 30, 2009 $3,028  $881  $98  $(1,020) $2,987 
September 30, 2008 $3,444  $1,342  $(206) $(1,325) $3,255 
                 
(in thousands) Total  Level 1  Level 2  Level 3 
Assets:                
Money market (1) $81  $81  $  $ 
Equity indexed derivatives (2)  176      176    
             
Total $257  $81  $176  $ 
             
Liabilities:                
Foreign currency contracts (3) $5,709  $  $5,709  $ 
             
 
(1) Effects of exchange rate changesIncluded in “cash and cash equivalents” in the condensed consolidated balance sheets
(2)Included in “short-term investments” in the condensed consolidated balance sheets. The gross unrealized loss is not material.
(3)Included in “other long-term liabilities” or “other accrued liabilities” in the condensed consolidated balance sheets
13. CommitmentsNote 4: Derivative Securities
All derivatives, whether designated in hedging relationships or not, are required to be recorded on the consolidated balance sheets at fair value as either assets or liabilities. If the derivative is designated as a fair-value hedge, the changes in the fair value of the derivative and Other Contingencies
Revenues generated from international operationsof the hedged item attributable to the hedged risk are generally denominatedrecognized in earnings. If the derivative is designated as a cash flow hedge or net investment hedge, the effective portions of changes in the fair value of the derivative are recorded in other comprehensive income and are recognized in earnings when the hedged item affects earnings; ineffective portions of changes in fair value are recognized in earnings.

8


Dionex operates on a global basis and is exposed to foreign currencies. We have entered into forwardcurrency exchange rate fluctuations in the normal course of its business. As part of its risk management strategy, Dionex uses derivative instruments to manage exposures to foreign exchange contractscurrency. The objective is to hedge against fluctuations of intercompany account balances. Market valueoffset gains and losses resulting from these exposures with losses and gains on thesethe derivative contracts used to hedge them, thereby reducing volatility of earnings or protecting fair value of assets and liabilities. Dionex does not have any leveraged derivatives nor use derivative contracts are substantially offset by fluctuations in the underlying balances being hedged, and the net financial impact is not expected to be material in future periods. At September 30, 2009, we had forward exchange contracts to sell foreign currencies totaling $18.1 million (including approximately $11.2 million in Euros, $5.2 million in Japanese yen, $0.9 million in Australian dollars and $0.8 million in Canadian dollars). The foreign exchange contracts outstanding at the end of the period mature within one month. Consequently, contract values and fair market values are the same. In March 2007, we entered intofor speculative purposes.
Net Investment Hedge
Dionex uses a $10.0$10 million cross-currency swap arrangement for Japanese Yenyen that maturesexpires in March 2010. Starting January 2008, we determined that this cross-currency swap qualified2012 to hedge the exchange rate exposure of our net investment in our Japanese subsidiary. Dionex considers the impact of its counterparty’s credit risk on the fair value of the contract as well as the ability of each party to execute under the contract. Dionex assessed and documented hedge effectiveness of the contract and designated it as a net investment hedge. Ashedge at the inception date, January 1, 2008. We reassess hedge effectiveness on a result, duringquarterly basis. The gain or loss related to the three months ended September 30, 2009 and 2008, we marked to market decreases in valueeffective portion of $901,000 and $110,000, respectively,the hedge is reported in accumulated other comprehensive income as part of the foreign currency translation adjustment.adjustment, and the gain or loss related to the ineffective portion, if any, is reported in other income (expense).
WeOther Derivatives
Other derivatives not designated as hedging instruments consist primarily of foreign exchange forward contracts with high quality financial institutions to manage our exposure to the impact of fluctuations in foreign currency exchange rates on our intercompany receivables balances. Principal hedged currencies include the Euro, Japanese yen, Australian dollar and Canadian dollar. The periods of these forward contracts is approximately 30 days and have varying notional amounts that are intended to be consistent with changes in the underlying exposures and require Dionex to exchange foreign currencies for U.S. dollars at maturity. Gains (losses) on these contracts are reported as other income (expense) in the current period earnings.
Total gross notional amounts for outstanding derivatives were as follows:
         
  September 30,  June 30, 
(in thousands) 2010  2010 
Derivatives not designated as hedging instruments        
Currency forwards:        
Euro $23,793  $17,659 
Japanese yen  6,683   4,282 
Australian dollar  1,052   791 
Canadian dollar  1,205   853 
Derivatives designated as hedging instruments        
Currency swaps  10,000   10,000 
       
Total $42,733  $33,585 
       
The following table shows derivative instruments measured at gross fair value and balance sheet location on the condensed consolidated balance sheet:
                 
  September 30, 2010 June 30, 2010
  Accrued Other Long- Accrued Other Long-
(In thousands) Liabilities Term Liabilities Liabilities Term Liabilities
Derivatives designated as hedging instruments                
Currency swaps $  $4,211  $  $3,390 
Derivatives not designated as hedging instruments                
Currency forwards $1,498  $  $290  $ 

9


The following table shows the effect of derivative instruments designated as hedging instruments and not designated as hedging instruments in the condensed consolidated statements of operations in the three months ended September 30:
         
(In thousands) 2010 2009
Derivatives designated as hedging instruments        
Net investment hedges        
Unrealized gain/ (loss) recognized in other comprehensive income on derivatives $(821) $(901)
Realized gain/ (loss) reclassified from other comprehensive income into income $  $ 
Derivatives not designated as hedging instruments        
Currency forwards        
Realized gain / (loss) included other income/(expense), net $(2,161) $(661)
Note 5: Balance Sheet Details
The following tables provide details of selected balance sheet items:
         
  September 30,  June 30, 
(in thousands) 2010  2010 
Inventories:
        
Finished goods $25,733  $23,788 
Work in process  1,542   1,781 
Raw materials  14,287   11,889 
       
  $41,562  $37,458 
       
         
  September 30,  June 30, 
  2009  2010 
Property, Plant and Equipment, net:
        
Land $27,859  $25,098 
Buildings and improvements  50,407   48,396 
Machinery, equipment and tooling  53,082   50,411 
Furniture and fixtures  13,219   12,194 
Construction-in-progress  25   13 
       
   144,592   136,112 
Accumulated depreciation and amortization  (63,969)  (60,050)
       
Property, plant and equipment, net $80,623  $76,062 
       
Depreciation expense was $2.6 million and $2.2 million in three months ended September 30, 2010 and 2009, respectively.
Note 6: Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill were as follows for the three months ended September 30, 2010:
     
(in thousands)    
Balance as of June 30, 2010 $35,013 
Additions  12 
Foreign currency translation impact  888 
    
Balance as of September 30, 2010 $35,913 
    
Intangible assets (net of accumulated amortization) were as follows:
                         
  As of September 30, 2010  As of June 30, 2010 
  Carrying  Accumulated      Carrying  Accumulated    
(in thousands) Amount  Amortization  Net  Amount  Amortization  Net 
Patents and trademarks $8,788  $(2,730) $6,058  $8,788  $(2,580) $6,208 
Developed technology  9,840   (1,332)  8,508   14,893   (10,456)  4,437 
Customer relationships  5,322   (2,234)  3,088   5,119   (1,905)  3,214 
                   
Total $23,950  $(6,296) $17,654  $28,800  $(14,941) $13,859 
                   
As a result of certain acquisitions, Dionex recorded trade names (intangible assets) totaling $2.8 million, which is not subject to amortization and is included in Patent and trademarks.

10


Amortization expense related to all finite intangible assets was $0.8 million and $0.3 million in three months ended September 30, 2010 and 2009, respectively. Estimated future amortization expense related to finite lived intangible assets as of September 30, 2010 is as follows:
     
  Remaining
  Amortization
(in thousands) Expense
Remainder of Fiscal 2011 $2,394 
Fiscal 2012  2,878 
Fiscal 2013  2,234 
Fiscal 2014  1,775 
Fiscal 2015  1,374 
After Fiscal 2015  4,179 
     
Total $14,834 
     
Note 7: Financing Arrangements
Dionex has unsecured credit agreements with domestic and international financial institutions. The agreements provide for revolving unsecured lines of credit that we utilize primarily for our general corporate purposes, including stock repurchases and working capital needs. As of September 30, 2009,2010, we had a total of $14.0$29.2 million in available lines of credit, with outstanding borrowings of $15.1 million maturing on December 31, 2009.
On July 1, 2008, we acquired a 100% ownership2010 at an annual interest in a Swedish company, inrate of 1.9%, under which we previously heldhad borrowed $17.4 million.
One of our foreign subsidiaries transfers certain customer receivables to financial institutions at a 30% equity interest with a carrying amountdiscount up to approximately 2% (“discounted notes”) and accounts for these transfers as sales. The purpose of $760,000 at June 30, 2008, using a combinationthese transfers is to facilitate the funding of cash and earn-out payment arrangements. The total purchase considerationoutstanding customer receivables by the Company. In the unlikely event that there is failure by the customers to repay the financial institutions for the incremental 70% ownership interest was approximately $1.5 million, excluding contingent earn-out payments based on a percentage of net income in 2009 through 2011. This acquisition allowed us to take control of our Swedish distributor for the purpose of further expanding the business. Approximately $952,000 of the purchase consideration was paid during the quarter ended September 30, 2008, with the remaining $580,000 payable on July 1, 2011 and included within other long-term liabilities at September 30, 2009. There were no earn-out payments recorded for the fiscal year ending June 30, 2009.
We enter into standard indemnification agreements with many of our customers and certain other business partners in the ordinary course of business. These agreements include provisions for indemnifying the customer against any claim broughtdiscounted notes sold by a third party to the extent any such claim alleges that our product infringes a patent, copyright or trademark, or violates any other proprietary rights of that third party. The maximum potential amount of future payments we couldDionex, Dionex would be required to makerepurchase the discounted notes back, up to the specified amount outstanding. Under no other circumstance is Dionex obligated or do we have a right to repurchase these discounted notes. Dionex has determined that the fair value of these contingent liabilities under these indemnification agreements isarrangements are not estimable, however, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification agreements. No material claims for such indemnifications were outstanding as of September 30, 2009. We have not2010 based on past experience of transferring discounted notes, which considers customers’ credit quality, historical loss experience, and whether the repurchase (if required in the event of a default) is probable and reasonably estimable. The length of time that these discounted notes are outstanding is approximately 90 days and during the three-months ended September 30, 2010, Dionex recorded any liabilitiesno losses as a result of customers’ failures to repay the financial institutions. Total discounted notes transferred to the financial institutions during the three months ended September 30, 2010 was $1.2 million and outstanding discounted notes sold as of September 30, 2010 was approximately $1.2 million.
Note 8: Warranty
Dionex accrues estimated product warranty costs at the time of sale, which are included in cost of sales in the consolidated statements of operations. While Dionex engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component supplies, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. The amount of the accrued warranty liability is based on historical information, such as past experience, product failure rates, number of units repaired and estimated costs of material and labor. The liability is reviewed for reasonableness at least quarterly.
The changes in the warranty provision were as follows during the three months ended September 30:
         
(in thousands) 2010  2009 
Balance, beginning $2,532  $3,028 
Additions  1,266   881 
Effects of foreign currencies exchange  144   98 
Settlements  (1,325)  (1,020)
       
Balance, end $2,617  $2,987 
       
Note 9: Stock-Based Compensation
Dionex’s Board of Directors authorized the 2004 Equity Incentive Plan (the “2004 Plan”). Shares reserved for future issuance under the 2004 Plan may be used for grants of stock options (“options”), restricted stock units (“RSU”), and other types of awards.
Dionex also sponsors the Employee Stock Purchase Plan (the “ESPP”) in which eligible employees may contribute up to 10% of their base compensation to purchase shares of common stock at a price equal to 85% of the lower of the market value of the stock at the beginning or end of each six-month offer period, subject to certain annual limitations. Employees purchased 18,831 shares during the

11


three months ended September 30, 2011 for approximately $1.1 million under the ESPP.
Performance Stock Units
Starting in the first quarter of fiscal 2011, Dionex issued performance stock units (“PSUs”) to certain executive officers. The number of shares ultimately received will depend on specified performance targets related to revenue and diluted earnings per share growth rates over a two-year performance period (the “performance period”). Fifty percent of the shares awarded vest at the end of the performance period and remaining shares vest twenty-five percent on each of the following two anniversaries after the performance period assuming continued service by the employee. Delivery of the shares occurs upon achievement of the targets and as of the vesting date.
Dionex estimates the fair value of the PSUs based on the number of PSUs that are expected to be earned multiplied by the market price of Dionex’s common stock on the date of grant. As the performance targets are considered performance conditions, the expense for these indemnification agreements atawards, net of estimated forfeitures, is recorded over the four year vesting period based on a graded accelerated vesting method.
The following table summarizes PSU activity under the 2004 Plan during the three months ended September 30, 2009 or June2010:
         
      Wtd. Avg.
      Grant-Date
  Shares Fair Value
PSUs outstanding as of June 30, 2010      
Granted  11,688  $76.30 
Vested      
Changes in PSUs due to performance conditions      
Forfeited      
         
PSUs outstanding as of September 30, 2010  11,688  $76.30 
         
As of September 30, 2010, there was $0.8 million in unrecognized compensation costs related to PSU granted under the 2004 Plan. These costs are expected to be recognized over a weighted average period of 3.8 years.
Restricted Stock Units
The following table summarizes RSU activity under the 2004 Plan during the three months ended September 30, 2010:
         
      Wtd. Avg.
      Grant-Date
  Shares Fair Value
RSUs outstanding as of June 30, 2010  87,776  $64.21 
Granted  34,241   76.30 
Released      
Canceled  (2,325)  67.18 
         
RSUs outstanding as of September 30, 2010  119,692  $67.61 
         
As of September 30, 2010, there was $5.9 million in unrecognized compensation costs related to RSU granted under the 2004 Plan. These costs are expected to be recognized over a weighted average period of 3.6 years.
Stock Options
The following table summarizes option activity under the 2004 Plan during the three months ended September 30, 2010:
                 
          Weighted    
          Average    
      Weighted  Remaining  Aggregate 
      Average  Contractual  Intrinsic 
  Options  Exercise  Term  Value 
  Outstanding  Price  (Years)  (in millions) 
Options outstanding as of June 30, 2010  1,474,627  $57.05         
Granted  215,412   76.30         
Exercised  (32,968)  44.21         
Canceled  (13,151)  68.77         
               
Options outstanding as of September 30, 2010  1,643,920  $59.74   6.56  $43.9 
               
Options vested and expected to vest as of September 30, 2010  1,601,557  $59.44   6.48  $43.2 
               
Exercisable as of September 30, 2010  965,177  $52.71   4.92  $32.6 
               

12


The total intrinsic value of options exercised during the first quarter of 2011 was $1.5 million. As of September 30, 2010, there was $12.2 million of total unrecognized compensation cost related to stock options. These costs are expected to be recognized over a weighted average period of 2.9 years.
The following assumptions were used to determine the fair value of the stock options using the Black-Scholes-Merton options pricing model for the three months ended September 30:
         
  2010 2009
Volatility  33%  33%
Risk-free interest rate  1.55%  2.53%
Expected life (in years)  4.7   4.6 
Expected dividend $0.00  $0.00 
Employee Stock Purchase Plan
The following assumptions were used to determine the fair value of ESPP shares for the three months ended September 30:
         
  2010 2009
Volatility  30%  36%
Risk-free interest rate  0.20%  0.30%
Expected life (in years)  0.50   0.50 
Expected dividend $0.00  $0.00 
The condensed consolidated statement of operations included the following stock-based compensation expense related to options, RSUs, PSUs, and ESPP for the three months ended September 30:
         
(in thousands) 2010  2009 
Cost of sales $234  $158 
Selling, general and administrative expenses  1,409   1,041 
Research and development expenses  330   379 
Tax benefit  (668)  (506)
       
Total $1,305  $1,072 
       
Note 10: Stockholders’ equity
Common Stock Repurchases
During the three months ended September 30, 2010, Dionex repurchased 187,183 shares of our common stock on the open market for approximately $14.0 million (at an average repurchase price of $74.54 per share), compared with 188,253 shares repurchased for approximately $11.2 million (at an average repurchase price of $59.36 per share) during the three months ended September 30, 2009.
14. Business Segment InformationComprehensive Income
We haveComprehensive income consists of two operating segments, CABUcomponents, net income and LSBU. CABU sells ion chromatographyother comprehensive income. Other comprehensive income refers to revenue, expenses, gains and accelerated solvent extraction products, serviceslosses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Dionex’s other comprehensive income consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency, unrealized gains (loss) on net investment hedge and related consumables. LSBU sells high performance liquid chromatography products, servicesunrealized gains and related consumables. These two operating segments are aggregated into one reportable segment for financial statement purposes.losses on available-for-sale securities, and net deferred gains and losses on these items.
Our salesThe components of products, installation and training services and maintenance within this reportable segmentcomprehensive income attributable to Dionex Corporation were detailed as follows for the three months ended September 30 (in thousands):
         
  2010  2009 
Net income, as reported $11,322  $10,586 
Foreign currency translation adjustments, net of taxes  9,215   4,862 
Unrealized loss on net investment hedge  (821)  (901)
Unrealized gain on securities available for sale, net of taxes     1 
       
Comprehensive income  19,716   14,548 
Comprehensive income (loss) attributable to the noncontrolling interests  361   250 
       
Comprehensive income attributable to Dionex Corporation $19,355  $14,298 
       

13


         
  Three Months Ended 
  September 30, 
  2009  2008 
Products $79,282  $81,834 
Installation and Training Services  2,480   2,608 
Maintenance  8,902   8,993 
       
  $90,664  $93,435 
       
Long-lived assets consist principally of property and equipment. No single customer contributed to more than 10% of revenue during the three months ended September 30, 2009, and revenue from services was less than 10% of revenue during the same periods.
15.Note 11: Income Taxes
As part of the process of preparing the condensed consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure and assessing changes in temporary differences resulting from differing treatment of items, such as depreciation, amortization and inventory reserves, for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the condensed consolidated balance sheets.
Accounting standardstandards relating to income taxes requiresrequire that we continually evaluate the necessity of establishing or changing a valuation allowance for deferred tax assets, depending on whether it is more likely than not that actual benefit of those assets will be realized in future periods. We have evaluated our deferred tax assets and concluded that it is more likely than not that the deferred tax assets will be benefited in the future; therefore, valuation allowance is not required. In addition, we adopted the provisions of the FASB’s accounting guidance related to the accounting for uncertainty in income taxes. TheThis accounting standard requires financial statement reporting of the expected future tax consequences of uncertain tax return reporting positions on the presumption that all relevant tax authorities possess full knowledge of those tax reporting positions, as well as all of the pertinent facts and circumstances, but it prohibits any discounting of any of the related tax effects for the time value of money.
Our total amount of unrecognized tax benefits as of JuneSeptember 30, 20092010 was $14.1$8.1 million, of which $3.2$1.9 million, if recognized, would affect our effective tax rate, compared to $8.0 million on June 30, 2010, of which $1.9 million, if recognized, would have affected our effective tax rate. The liability for income taxes associated with uncertain tax positions is classified in deferred and other income taxes payable. For the three months ended September 30, 2009, we have recorded an increase of $668,000 in unrecognized tax benefits as a result of our ongoing evaluation of uncertain tax positions of which $120k if recognized would affect our effective tax rate.
We record interest and penalties related to unrecognized tax benefits in income tax expense. At JuneSeptember 30, 2009,2010, we had approximately $2.0$1.9 million accrued for estimated interest related to uncertain tax positions.positions compared to approximately $1.7 million on June 30, 2010. During the three months ended September 30, 2009 and 2008,2010, we accrued a total of $385,000 and $261,000, respectively$175,000 in interest on these uncertain tax positions. At September 30, 2010, we had approximately $69,000 accrued for estimated penalties related to uncertain tax positions compared to approximately $69,000 on June 30, 2010. During the fiscal year ended June 30, 2010, we accrued no additional penalties on these uncertain tax positions.
Included in our balance of income tax liabilities, accrued interest, and accrued penalties at September 30, 2010 of $10.2 million, is $3.9 million related to tax positions for which it is reasonably possible that the statute of limitations will expire in various jurisdictions within the next twelve months.
We are subject to audit by the Internal Revenue Service and the California Franchise Tax Board for the fiscal year 2005years 2006 through the fiscal year 2008.2009. As we have operations in most other US states, other state tax authorities may assess deficiencies related to prior year activities; however, the years open to assessment vary with each state. We also file income tax returns for non-US jurisdictions; the most significant of which are Germany, Japan, the UK and Hong Kong. The years open to adjustment for Germany are for the fiscal years 2004 through 2009, fiscal years 2004 through 2009 for the UK and Hong Kong areand fiscal years 2003 through 2008. The years open to adjustment2009 for Japan are fiscal years 2002 through 2008.Japan.
A number of years may elapse before an uncertain tax position is audited and ultimately settled. It is difficult to predict the ultimate outcome or the timing of resolution for uncertain tax positions. It is reasonably possible that the amount of unrecognized tax benefits could significantly increase or decrease within the next twelve months. These changes could result from the settlement of ongoing litigation, the completion of ongoing examinations, the expiration of the statute of limitations, or other circumstances. At this time, an estimate of the range of the reasonably possible changeschange cannot be made.
16. Fair Value MeasurementsNote 12: Commitments and Contingencies
EffectiveIn July 1, 2008, we adopted an Accounting Standard Update for fair value measurements for all financial assetsDionex acquired a Swedish company using a combination of cash and liabilities. Fair value are defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing assets or liabilities. When determining the fair value measurementspost acquisition earn-out payment arrangements.

14


Under the purchase agreement, earn-out payments of 70% for assetsfiscal 2009, 30% for fiscal 2010 and liabilities required or permitted30% for 2011 as a percentage of the acquired company’s net income are payable to be recordedthe seller at fair value, we consider the principal or most advantageous marketend of each fiscal year. Each earn-out payment is contingent upon results of operations in which no payments were made during the three months ended September 30, 2010.
Certain facilities and equipment are leased under non-cancelable operating leases. Dionex generally pays taxes, insurance and maintenance costs on leased facilities and equipment. Rental expense for all operating leases was $1.6 million and $2.0 million in the three months ended September 30, 2010 and 2009, respectively.
Minimum rental commitments under these assets and liabilities would be transacted.
Fair value hierarchy prioritizes the inputs to fair value measurement into three levels:
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs are those other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 inputs are unobservable inputs for the asset or liability.
The following table summarizes our financial assets and liabilities measured at fair value on a recurring basisnon-cancelable operating leases were as follows as of September 30, 2009 (in thousands):2010:
                 
      Fair Value Measurements at September 30, 2009 
      Quoted Prices  Significant    
      In Active  Other  Significant 
      Markets or  Observable  Unobservable 
      Identical Assets  Inputs  Inputs 
Description Total  (Level 1)  (Level 2)  (Level 3) 
Assets:                
Money market $7,151  $7,151  $  $ 
Equity indexed derivatives  452      452    
             
Total $7,603  $7,151  $452  $ 
             
     
(In thousands)    
Less than 1 Year $6,277 
1-2 Years  2,992 
2-3 Years  1,601 
3-4 Years  845 
4-5 Years  306 
After 5 Years  1,381 
    
Total $13,402 
    
Reported as:Dionex enters into standard indemnification agreements with many of our customers and certain other business partners in the ordinary course of business. These agreements include provisions for indemnifying the customer against any claim brought by a third party to the extent any such claim alleges that our product infringes a patent, copyright or trademark, or violates any other proprietary rights of that third party. The maximum potential amount of future payments Dionex could be required to make under these indemnification agreements is not estimable, however, Dionex has not incurred any costs to defend lawsuits or settle claims related to these indemnification agreements. No material claims for such indemnifications were outstanding as of September 30, 2010. Dionex has not recorded any liabilities for these indemnification agreements as of September 30, 2010 or June 30, 2010.
                 
      Fair Value Measurements at September 30, 2009 
      Quoted Prices  Significant    
      In Active  Other  Significant 
      Markets or  Observable  Unobservable 
      Identical Assets  Inputs  Inputs 
Description Total  (Level 1)  (Level 2)  (Level 3) 
Assets:                
Cash equivalents (1) $7,151  $7,151  $  $ 
Short-term investments  452      452    
             
Total $7,603  $7,151  $452  $ 
             
Note 13: Business Segment Information
17. Subsequent Events
We have evaluated subsequent events through November 6, 2009, the day our condensed consolidatedThe accounting standard for segment reporting establishes standards for reporting information about operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports of public business enterprises. It also establishes standards for related disclosures about products and services, geographic areas and major customers. Our business activities, for which discrete financial information is available, are regularly reviewed and evaluated by the chief operating decision maker (our Chief Executive Officer). As a result of this evaluation, Dionex determined that it has two operating segments: Chemical Analysis Business Unit (“CABU”) and Life Sciences Business Unit (“LSBU”).
CABU sells ion chromatography and sample preparation products, chromatography data systems software, services and related consumables. LSBU sells High Performance Liquid Chromatography (“HPLC”) products, chromatography data systems software, services and related consumables. These two operating segments are aggregated into one reportable segment for financial statement purposes. Both operating segments have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution and regulatory environments. Because of these similarities, the two segments have been aggregated into one reporting segment for financial statement purposes.
Net sales for our products and services were as follows for the quarterthree months ended September 30:
         
(in thousands) 2010  2009 
Products $86,452  $79,282 
Installation and Training Services  2,580   2,480 
Maintenance  13,842   8,902 
       
  $102,874  $90,664 
       
No individual customer accounted for more than 10% of net sales during the three months ended September 30, 2009 were issued2010 and concluded there are no additional adjustments to the condensed consolidated financial statements or disclosures required.2009.

15


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Statement Regarding Forward-Looking Statements
Except for historical information contained herein, the discussion below and in the footnotes to our financial statements contained in this Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, and are made under the safe harbor provisions thereof. Such statements are subject to certain risks, uncertainties and other factors that may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements, or industry results, expressed or implied by such forward-looking statements. Such risks and uncertainties include, among other things: general economic conditions, foreign currency fluctuations, risks associated with international sales, credit risks, fluctuations in worldwide demand for analytical instrumentation, fluctuations in quarterly operating results, competition from other products, existing product obsolescence, new product development, including market receptiveness, the ability to manufacture products on an efficient and timely basis and at a reasonable cost and in sufficient volume, the ability to attract and retain talented employees and other risks as described in more detail below under the heading “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements that reflect management’s analysis only as of the date hereof. We undertake no obligation to update these forward-looking statements.
Overview
Dionex Corporation designs, manufactures, markets and services analytical instrumentation and related accessories and chemicals. Our products are used to analyze chemical substances in the environment and in a broad range of industrial and scientific applications. Our systems are used in environmental analysis and by the pharmaceutical, life sciences, chemical/petrochemical, power generation, food and electronics industries in a variety of applications.
Our current portfolio of liquid chromatography (LC) systems is focused in two product areas: ion chromatography (IC) and high performance liquid chromatography (HPLC). In addition, we offer a mass spectrometer detector that can be coupled with either IC or HPLC systems. For sample preparation, we provide accelerated solvent extraction (ASE®) systems and AutoTrace® instruments. In addition, we also develop and manufacture columns, consumables, suppressors, detectors, automation, and software analysis systems for use in or with liquid chromatography systems. All these products can be used to analyze chemical substances in the environment and in a broad range of industrial and scientific applications.
During the last three quarters, we saw some declinepast quarter, Dionex experienced steady growth in customercertain of its end-user markets, including the life sciences, chemical/petrochemical, food and beverage and electronics markets. Demand from our customers in the environmental and electronics markets was relatively flat, while demand mainly driven by weaker economic conditions in some countries and/or specific end-user markets. We believe our second quarter will continue to be affected. Despite the weakness caused by the current economic conditions, we are very pleased with our resultspower market was lower for the first quarter. We exceededexperienced first quarter organic sales growth in all three of our internal expectations and guidance for bothmajor geographic regions. North America continued its strong sales and earnings per share forperformance from the fourth quarter of fiscal 2010 growing 22% compared with the first quarter. Our gross margin was in line with our expectations and we closely managed our operating expenses. We were also ablequarter of last year due to complete the acquisition of certain HPLC products line from ESA Biosciences, Inc., which further strengthened our HPLC portfolio. We believe the acquisition expanded our life sciences market opportunities, particularly in clinical research applications. Looking at our end customers markets, net salesstrong performance in our life sciences marketscience, chemical/petrochemical and food and beverage markets. In Europe, sales were up 9% in the first quarterlocal currencies, but were negatively affected by currency fluctuation which resulted in 1% growth in reported dollars compared towith last year. In Asia Pacific, sales in the first quarter of fiscal 2009, showing growth2011 grew 21% in all of our major geographic regions. Net sales in our environmental and food and beverage markets were flat for the quarter compared to the first quarter of fiscal 2009, with mixed results on a geographic basis. Finally, net sales in our chemical/petrochemical and our high purity water markets (electronics and power) were down in the first quarter compared to the first quarter of fiscal 2009.
Looking at sales by major geographic region, net sales in North America were down slightly for the quarter compared to the first quarter of fiscal 2009. We believe this performance in our North American business represents a stabilization of our business in this region compared with the last two quarters. In Europe, first quarter sales declined in both reported dollars and 17% in local currency compared to the first quarter of fiscal 2009. We saw weaknessdriven by continued strong sales growth in all of our markets except life sciences which continued to grow. Our Asia Pacific region continued its strongest performance as sales in this region grew in both reported dollarsIndia, Korea and local currency for the first quarter.Japan.

16


Results of Operations
Summary
Net sales for the first quarterThe following table summarizes our consolidated statements of fiscal 2010 were $90.7 million, compared with $93.4 million reported for the same period in the prior year, reflecting a decrease of 3%. Operating income for the quarter was $16.5 million, a decrease of 15.4% over operating income for the first quarter of fiscal 2009 of $19.5 million. Cash flow from operating activities during the quarter was $22.9 million compared with $8.7 million for the first quarter of fiscal 2009, reflecting an increase of 162%. Our gross profit margin for the quarter was 65.8%,2011 and 2010 as a decrease compared to 67.1% for the same period last year. Selling, general and administrative expenses were 39.7%percentage of net sales during the quarter, compared to 38.7% reported in the same period last year. Research and product development expenses for the quarter were 7.9% ofperiods indicated:
                 
  Q1 2011 Q1 2010
      % of        
      Net      % of Net 
(in thousands) Dollars  Sales  Dollars  Sales 
     
Net sales $102,874   100.0% $90,664   100.0%
Cost of sales  36,472   35.5%  31,041   34.2%
             
Gross profit  66,402   64.5%  59,623   65.8%
Operating expenses:                
Selling, general and administrative  40,266   39.2%  35,983   39.7%
Research and product development  8,013   7.8%  7,172   7.9%
             
Total operating expenses  48,279   47.0%  43,155   47.6%
             
Operating income  18,123   17.6%  16,468   18.2%
Interest income, net  27   0.0%  47   0.0%
Other income (expense), net  (1,038)  (1.0)%  40   0.1%
             
Income before taxes  17,112   16.6%  16,555   18.3%
Taxes on income  5,790   5.6%  5,969   6.6%
             
Net income  11,322   11.0%  10,586   11.7%
Less: Net income attributable to noncontrolling interests  361   0.4%  250   0.3%
             
Net income attributable to Dionex $10,961   10.6% $10,336   11.4%
             
Net sales
Consolidated net sales up slightly from the 7.5% reported in the same period last year. Diluted earnings per share decreased 10.9% to $0.57 for the first quarter, compared to $0.64 reported in the same period last year.
Net sales
Net sales for the first quarter of fiscal 2010 were $90.7 million, compared with $93.4 million reported for the same period in the prior year, reflecting a decrease of 3%, including a $1.9 million adverse currency effect. Net sales in North America decreased by 0.4%increased 13% in the first quarter of fiscal 2010 to $25.0 million,2011 compared to $25.1 million duringsame period in prior year (excluding the net impact of unfavorable currency movements, net sales increased 15%). Our portfolio of HPLC systems was the largest contributor to our consolidated net sales growth in part as a result of our acquisition of the ESA Life Sciences Tools business (“ESA products”) in the first half of fiscal 2010, combined with the introduction of our UHPLC+ systems in fiscal 2010. Dionex is subject to the effects of currency fluctuations, which have an impact on net sales. Currency fluctuations decreased net sales by 2% in the first quarter of fiscal 2011 compared to prior-year period.
Net sales increased across all major regions primarily as a result of a recovering global economy, combined with continued strength in China, India, and other emerging markets. Net sales outside of North America accounted for 70% and 73% of net sales in the first quarter of 2011 and 2010, respectively. Sales directly to our end-user customers accounted for 95% in those same periods. International distributors and representatives in Europe, Asia, and other international markets accounted for the remaining percentage of net sales.
Net sales from a regional perspective
North America- Net sales in this region increased 22% in the first quarter of fiscal 2011 compared to the same period in the prior year primarily due to

16


lower the demand fromfor our environmental andproducts in the life science, food and beverage customers. However,and power markets. The overall demand in this performance showed stabilizationregion was driven by our HPLC instruments, the ESA products and by our new ICS-5000 Capillary RFIC Systems (“ICS-5000”), introduced in demand compared with the previous two quarters.second half of fiscal 2010.
Europe- Net sales in Europe decreased by 12% to $35.1 millionthis region increased 1% in reported dollars in the first quarter of fiscal 2010,2011 compared to $39.9 millionsame period in prior-year (excluding the net impact of unfavorable currency movements, net sales increased 9%). The overall growth was primarily due to strong demand in the chemicals and food and beverage markets, offset by softness in the life science and environmental markets. From a product perspective, growth in this region was driven by our HPLC portfolio, specifically ESA products added during fiscal 2010 and the introduction of the new UHPLC+ systems.
Asia / Pacific- Net sales in this region increased 21% in reported dollars in the first quarter of fiscal 2011 compared to the same period in prior year (excluding the net impact of favorable currency movements, net sales increased 17%). The overall growth was primarily due to continued strength in the countries of India, Korea and Japan as well as overall strength in the life sciences and chemical markets in this particular region.

17


Our continued effort to make investments in our sales and service organization was pivotal to the growth in this region, combined with the revenue contributed from the ESA products.
Net sales from a product line perspective
IC - Net sales of our IC portfolio of products increased 8% in the first quarter of 2011 compared to the same period in prior year primarily due to growth in North America and Asia/Pacific regions driven by the recovery of the global economy and higher demand in the life science and food and beverage markets for our IC systems, consumables and related services.
HPLC - Net sales of our HPLC portfolio of products increased 31% in the first quarter of 2011 compared to the same period in the prior year primarily due to the challenging economic environment and adverse currency fluctuations of $2.2 million. Excluding the impact of currency fluctuations, net sales generated from our ESA products acquired in Europe decreased by 7%the first half of fiscal 2010. Excluding net sales from our ESA products during the first quarter of fiscal 2011 and 2010, net sales increased 14% over the same comparable period as a result of the rebounding global economy from the past few quarters, and in part, due to $37.3 millionthe introduction of our UHPLC+ systems in fiscal 2010.
Gross Profit
Gross Profit as a percentage of net sales in the first quarter of fiscal 2011 and 2010, due to weaknesses in all of our markets except life sciences which continue to grow.respective, were 64.5% and 65.8%, respectively. The Asia/Pacific region continued its strong performance as it grew 8% in reported dollars and 6% in local currency for the first quarter compared to the first quarter of fiscal 2009. Sales growth1.3 percentage point decline was driven by a strong performanceincreased sales of our ESA products acquired in China. We saw weaker sales results in Japan and Korea compared to previous quarters, though order flows improved in the last month of the quarter.
We are subject to the effects of foreign currency fluctuations that have an impact on net sales. Overall, currency fluctuations decreased reported net sales for the three months ended September 30, 2009 by $1.9 million, or 2.0% compared to the same quarter last year.
Percentage changes in net sales over the corresponding period in the prior year were as indicated in the table below:
Three Months
Ended
September 30, 2009
Percentage change in net sales
Total:-3.0%
By geographic region:
North America-0.4%
Europe-12.3%
Asia/Pacific7.9%
Percentage change in net sales excluding currency fluctuations over the corresponding period in the prior year were as indicated in the table below:
Three Months
Ended
September 30, 2009
Percentage change in net sales excluding currency fluctuations
Total:-1.0%
By geographic region:
North America0.5%
Europe-6.7%
Asia/Pacific5.8%
Gross margin
Gross margin for the first quarter of fiscal 2010 was 65.8%,which currently have a decrease from the 67.1% gross profit margin reported in the first quarter last year. The difference was due to a number of factors, including a change in the geographical mix with a weaker performance in Europe, faster HPLC sales growth and higher deferred revenue. We expect ourlower gross margin to be in the range of 66% to 67% for the fiscal year 2010.than our corporate average, as well as overall regional sales mix.
Operating expenses
Operating expenses for the first quarter of fiscal 2010 were $43.2 million, unchanged compared to the same quarter last year. As a percentage of net sales, operating expenses were 47.6% for the first quarter of fiscal 2010, an increase from the 46.3% of sales reported in the first quarter of fiscal 2009. The effects of foreign currency fluctuations decreased total operating expenses by $1.4 million, or 3.2%, for the quarter ended September 30, 2009, compared to an increase of 5.0% during the same period in the prior year.Selling, General and Administrative
Selling, general and administrative (SG&A) expenses were $36.0 million for the first quarter of fiscal 2010, compared with $36.2 million for the same quarter of fiscal 2009. Asas a percentage of net sales SG&A expenses were 39.7%approximately 39% and 40% in the first quarter of fiscal 2011 and 2010, compared to 38.7% the same period in fiscal 2009. Effects of foreign currency fluctuations decreasedrespectively. SG&A expenses by $1.2increased $4.3 million, or 3.3%, in the first quarter of fiscal 2010. SG&A expenses, excluding currency effects, grew by $0.9 million, or 2.7%, compared to the first quarter of fiscal 2009,12% primarily due to ourheadcount increases, including staff added from the ESA acquisition and increased selling and other expenses for the continued expansion efforts to increase our presence in theEurope and Asia/Pacific regionregions.
Research and certain one-time expenses related to our acquisition during the quarter.Product Development
Research and product development (R&D) expenses as a percentage of net sales were $7.2 million for the first quarter of fiscal 2010, an increase of $0.2 million,

17


or 2.0%, from $7.0 million reportedapproximately 8% in the first quarter of fiscal 2009. As2011 and 2010. While R&D expenses increased $841,000, or 11.7% primarily due to the headcount increases from the ESA acquisition, R&D expenses as a percentage of net sales R&D expenses increased marginally to 7.9%was in line between both periods.
Interest Income
Interest income in the first quarter of fiscal 2011 and 2010 when compared towas $60,000 and $83,000, respectively. Our interest income was affected by a combination of the 7.5%maturity of one of our short-term investments and lower interest rates in the U.S. and Europe in the first quarter of fiscal 2009.2011.
Income taxesInterest Expense
The effective tax rateInterest expense in the first quarter of fiscal 2011 and 2010 was 36.6%, reflecting$33,000 and $36,000, respectively. Our interest expense was affected the combination of a decrease from 38.0% reported forhigher average balance in our borrowing under the line of credit, offset by lower interest rates in the first quarter of fiscal 2009.2011.
Other Income (Expense), Net
Other income (expense), net in the first quarter of fiscal 2011 and 2010 was ($1.0 million), and $40,000, respectively. The relativechanges were primarily due to losses on foreign currency transactions in the first quarter of fiscal 2011.
Taxes on Income
Our tax rate may change over time as the amount and mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using our projected annual pre-tax income and is affected by tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

18


The taxes on income in the first quarter of fiscal 2011 and 2010 was $5.8 million and $5.9 million, respectively, representing an effective tax rate of 33.8% and 36.6%, respectively. The decrease in our tax rate was primarily due to lower research tax credits in last fiscal year, as the federal statute had expired.accrued interest on exposures. We anticipate that our tax rate for the rest of the fiscal year2011 will be in the range of 34.0%33% to 35.0%34%.
Net incomeIncome Attributable to Noncontrolling Interests
Net income attributable to Dionex Corporationnoncontrolling interests in the first quarter of fiscal 2011 and 2010 decreased 12.7%was $361,000 and $250,000, respectively. Net income attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net income recorded by three majority-owned international subsidiaries. The increase was due to better performance in India and Brazil.
Net Income Attributable to Dionex Corporation
Net income in the first quarter of fiscal 2011 and 2010 was $11.0 million and $10.3 million, compared with $11.8 million reported for the same period last year.respectively, while diluted earnings per share were $0.62 and $0.57, respectively.
Liquidity and Capital Resources
AtAs of September 30, 2009,2010, we had cash and cash equivalents and short-term investments of $78.7$77.0 million. Our working capital was $117.2$143.7 million, an increase of $21.2$26.5 million from $96.0$117.2 million reported atas of September 30, 2008.2009.
Cash generated by operating activities for the three months ended September 30, 2009first quarter in fiscal 2011 was $22.9$10.5 million, compared with $8.7$22.9 million for the same period last year. A lower level of prepaid income taxes, due to a refund of the taxes, an increase in deferred revenues due to a higher level of uninstalled systems and software, a decrease in accounts receivable due to lower sales and higher income taxes payable due to lower tax payments contributed to higher operating cash flows. These changes were partially offset by a decrease to operating cash from an increase in inventory as we prepared for higher shipments in the second quarter and a decrease in accounts payable and accrued liabilities for employee compensation.due to higher payments made in the quarter.
Cash used for investing activities was $23.6$9.4 million induring the first three monthsquarter of fiscal 2010.2011. Capital expenditures forduring the three monthsfirst quarter of fiscal 20102011 were $2.8$5.2 million which included purchases related to our general operations, purchase of land required for expansion of our IT platformmanufacturing capacity in Germering, Germany, and refurbishmenteffects of foreign currency translations. In addition, we also negotiated and completed a building in Sunnyvale. Additionally, $21.1paid-up royalty for $4.5 million was paid in connection with the acquisition of the assets and liabilities of the LST and Laboratory Services business ofrelated to our ESA Biosciences Inc, of which approximately $3M was for the building in which they currently operate.products.
Cash provided by financing activities was $7.3$3.2 million induring the three monthsfirst quarter of fiscal 2010. The cash generated was2011. Financing activities consisted primarily attributable to the repurchase of 188,253 shares of our common stock for $11.2 million, offset by $3.3 million in proceeds from issuance of common stock and $15.1 million inrepurchases, partially offset by proceeds from increased borrowingissuances of shares pursuant to our equity incentive plans, repayment of short-term obligations, and the tax benefits related to stock options in the acquisitionfirst quarter of the assets and liabilitiesfiscal 2011.
Our available lines of the LST and Laboratory Services businesscredit totaled $11.8 million as of ESA Biosciences Inc.
At September 30, 2009, we had utilized $15.1 million of our $29.1 million in committed bank lines of credit. The borrowings were used to finance our asset acquisition from ESA Biosciences, Inc.
2010. We believe that our cash flow from operating activities, currentoperations, our existing cash and cash equivalents and short-term investments and the remainder of our bank lines of credit will be adequate to meet our cash requirements for at least the next twelve12 months. The line of credit matures on December 31, 2011. The impact of inflation on our financial position and results of operations was not significant during any of the periods presented.

19


Contractual Obligations and Commercial Commitments
The following table summarizes our contractual obligations atas of September 30, 2009,2010, and the payments due in future periods (in thousands):
                                        
 Payments Due by Period  Payments Due by Period 
 Less        Less       
 Than 1 1-3 4-5 After 5  Than 1 1-3 4-5 After 5 
Contractual Obligations Total Year Years Years Years  Total Year Years Years Years 
Short-Term Borrowings $15,137 $15,137 $ $ $  $17,371 $17,371 $ $ $ 
Long-Term Debt Associated with Business Purchase 580  580    527 527    
Operating Lease Obligations 14,637 5,796 4,754 1,549 2,538  13,402 6,277 4,593 1,151 1,381 
                      
Total $30,354 $20,933 $5,334 $1,549 $2,538  $31,300 $24,175 $4,593 $1,151 $1,381 
                      

18


There have been no material changes to our operating lease obligations outside ordinary business activities since June 30, 2009. Our outstanding borrowings under our linesAs of credit increased to $15.1 million at September 30, 2009 from $0.62010, the liability for uncertain tax positions, net of offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and interest deductions was $1.9 million. As of September 30, 2010, the Company has accrued $1.9 million at June 30, 2009. These amounts are due in a period of less than one year.interest and $69,000 of penalties associated with its uncertain tax positions. The Company cannot conclude on the range of cash payments that will be made within the next twelve months associated with its uncertain tax positions.
The amounts above exclude liabilities recorded under the accounting provision related to income tax uncertainties, as we are unable to reasonably estimate the ultimate amount or timing of settlement.
New Accounting Pronouncements
Refer to Note 21 in the Notes to Condensed Consolidated Financial Statements section.
Critical Accounting Policies and Estimates
The preparation of condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. We evaluate our estimates, including those related to product returns and allowances, bad debts, inventory valuation, goodwill and other intangible assets, income taxes, warranty and installation provisions, and contingencies on an ongoing basis.
We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
There have been no significant changes during the three months ended September 30, 20092010 to the items that we disclosed as our critical accounting policies and estimates in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009.2010.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
We are exposed to financial market risks from fluctuations in foreign currency exchange rates, interest rates and stock prices of marketable securities. With the exception of the stock price volatility of our marketable equity securities, we manage our exposure to these and other risks through our regular operating and financing activities and, when appropriate, through our hedging activities. Our policy is not to use hedges or other derivative financial instruments for speculative purposes. We deal with a diversified group of major financial institutions to limit the risk of nonperformance by any one institution on any financial instrument. Separate from our financial hedging activities, material changes in foreign exchange rates, interest rates and, to a lesser extent, commodity prices could cause significant changes in the costs to manufacture and deliver our products and in customers’ buying practices. We have not substantially changed our risk management practices during fiscal 20092010 or the first three months of fiscal 20102011 and we do not currently anticipate significant changes in financial market risk exposures in the near future that would require us to change our current risk management practices.
Foreign Currency Exchange.Exchange
Revenues generated from international operations are generally denominated in foreign currencies. We have entered into forward foreign exchange contracts to hedge against fluctuations of intercompany account balances. Market value gains and losses on these hedge

20


contracts are substantially offset by fluctuations in the underlying balances being hedged, and the net financial impact is not expected to be material in future periods. AtAs of September 30, 2009,2010, we had forward exchange contracts to sell foreign currencies totaling $18.1million (including approximately $11.2$32.7 million, including approximately $23.8 million in Euros, $5.2$6.7 million in Japanese yen, $0.9$1.0 million in Australian dollars and $0.8$1.2 million in Canadian dollars). Atdollars. As of June 30, 2009,2010, we had forward exchange contracts to sell foreign currencies totaling $15.2approximately $23.7 million, (includingincluding approximately $9.8$17.7 million in Euros, $3.9$4.3 million in Japanese yen, $0.9$0.8 million in Australian dollars and $0.6$0.9 million in Canadian dollars).dollars. The foreign exchange contracts outstanding at the end of the period mature within one month. Consequently, contract values and fair market values are the same. AtAs of September 30, 20092010 and June 30, 2009,2010, we have $372,000approximately $1.5 million and $57,000,$0.3 million, respectively, in other current liabilities in the condensed consolidated balance sheets related to the foreign currency exchange contracts. For the three months ended September 30, 2010 and 2009, we recorded realized pre-tax losses of $661,000 related to the closed foreign exchange forward contracts. For the three months ended September 30, 2008, we recorded realized pre-tax gains of $979,000approximately $2.2 million and $0.7 million, respectively, related to the closed foreign exchange forward contracts.
In March 2007, we entered intoDionex uses a $10.0$10 million cross-currency swap arrangement for Japanese Yenyen that maturesexpires in March 2010.

19


Starting January 2008, we determined that this cross-currency swap qualified2012 to hedge the exchange rate exposure of our net investment in our Japanese subsidiary. Dionex considers the impact of its counterparty’s credit risk on the fair value of the contract as well as the ability to each party to execute under the contract. Dionex assessed and documented hedge effectiveness of the contract and designated it as a net investment hedge. This derivative instrument did not qualify for net investment hedge accounting and was deemed to be an ineffective hedge instrument because, at the inception date, January 1, 2008. We reassess hedge effectiveness on a quarterly basis. The effective portion of the gain or loss on the hedge transaction, there was no formal documentation of the hedging relationship and our risk management objective and strategy for undertaking the hedge. In January 2008, we completed our formal documentation of the hedging relationship and determined that the cross-currency swap qualified as a net investment hedge. As a result, during the three months ended September 30, 2009 and 2008, we marked to market decreases in value of $901,000 and $110,000, respectively,is reported in accumulated other comprehensive income as part of the foreign currency translation adjustment.
Interest and Investment Income.Income
Our interest and investment income is subject to changes in the general level of U.S. interest rates. Changes in U.S. interest rates affect the interest earned on our cash equivalents and short-term investments. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to our investment balances atas of September 30, 20092010 and June 30, 20092010 indicated that such market movement would not have a material effect on our business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending on our actual balances and changes in the timing and amount of interest rate movements.
Debt and Interest Expense.ExpenseAt
As of September 30, 2009, we2010, Dionex had notes payablean outstanding balance under a borrowing line of $15.1credit of $17.4 million. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to our outstanding debt balance atas of September 30, 2009,2010, indicated that such market movement would not have a material effect on our business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending on changes in the timing and amount of interest rate movements and the level of borrowings maintained by us.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our “disclosure controls and procedures” (as defined in rules promulgated under the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 20092010 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective at the “reasonable assurance” level. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a Company have been detected.
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Securities Exchange Act) during the period covered by this quarterly report on Form 10-Q that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

21


PART II. OTHER INFORMATION
ITEM 1A. RISK FACTORS
You should consider carefully the following risk factors as well as other information in this report before investing in any of our securities. If any of the following risks actually occur, our business operating results and financial condition could be adversely affected. This could cause the market price for our common stock to decline, and you may lose all or part of your investment. These risk factors include any material changes to, and supersede, the risk factors previously disclosed in our most recent annual report on Form 10-K.
A downturn in economic conditions could affect our operating results.
Our business, financial condition and results of operations have been affected by the weaker global economic conditions.conditions of the last several years. These conditions resulted in reduced sales of our products in the last quarters.two quarters of fiscal 2009 and the first two quarters of fiscal 2010. In a continued economic recession or under other adverse economic conditions, our customers may be less likely to purchase our products and vendors may be more likely to fail to meet

20


contractual terms. A further downturn in economic conditions or a slow recovery from the current recession may make it more difficult for us to maintain and continue our revenue growth and profitability performance resulting in a material adverse effect on our business.
Foreign currency fluctuations related to international operations may adversely affect our operating results.
We derived over 70% of our net sales from outside the United StatesU.S. in the first quarter of fiscal 2010 and expect to continue to derive the majority of net sales from outside the United StatesU.S. for the foreseeable future. Most of our sales outside the United StatesU.S. are denominated in the local currency of our customers. As a result, the U.S. dollar value of our net sales varies with currency rate fluctuations. Significant changes in the value of the U.S. dollar relative to certain foreign currencies could have a material adverse effect on our results of operations. In recent periods, our results of operations have been positively affected from the depreciation of the U.S. dollar against the Euro, the Japanese yen and several other foreign currencies, but there can be no assurance that this positive impact will continue. In the past, our results of operations have also been negatively impacted by the appreciation of the U.S. dollar against other currencies.
Economic, political and other risks associated with international sales and operations could adversely affect our results of operations.
Because we sell our products worldwide and have significant operations outside of the United States,U.S., our business is subject to risks associated with doing business internationally. We anticipate that revenue from international operations will continue to represent a majority of our total net sales. In addition, we expect that the proportion of our employees, contract manufacturers, suppliers, job functions and manufacturing facilities located outside the United StatesU.S. will increase. Accordingly, our future results could be harmed by a variety of factors, including:
  interruption to transportation flows for delivery of parts to us and finished goods to our customers;
 
  changes in a specific country’s or region’s economic, political or other conditions;
 
  trade protection measures and import or export licensing requirements;
 
  negative consequences from changes in tax laws;
difficulty in staffing and managing widespread operations;
 
  differing labor regulations;
 
  differing protection of intellectual property;
 
  unexpected changes in regulatory requirements; and
 
  geopolitical turmoil, including terrorism and war.
If we fail to effectively transition to our new and/or upgraded accounting information and technology infrastructure systems, it may have an adverse impact on our business and results of operations.

22


We may experience difficulties in transitioning to new or upgraded accounting information and technology infrastructure systems, including loss of data and decreases in productivity as personnel become familiar with new, upgraded or modified systems. Our accounting information and technology infrastructure systems will require modification and refinement as we grow and as our business and customers’ needs change, which could prolong the difficulties we experience with systems transitions, and we may not always employ the most effective information systems. If we experience difficulties in implementing new or upgraded accounting information and technology infrastructure systems or experience significant system failures, or if we are unable to successfully modify our accounting information and technology infrastructure systems and respond to changes in our customers’ needs in a timely manner, it may have an adverse impact on our business and results of operations.
We continually evaluate our system of internal controls over financial reporting and may make enhancements where appropriate, which may require significant resources.
     Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. We continually evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we could be subject to regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. In addition, failure to maintain adequate internal controls could result in financial statements that do not accurately reflect our financial condition. Implementing changes when necessary may take a significant amount of time, money, and management resources and may require specific compliance training of our directors, officers and other personnel.
Changes in our provision for income taxes or adverse outcomes resulting from examination of our income tax returns could adversely affect our results.
     Our provision for income taxes is subject to volatility and could be adversely affected by earnings being lower than anticipated in countries that have lower tax rates and higher than anticipated in countries that have higher tax rates; by changes in the valuation of our deferred tax assets and liabilities; by expiration of or lapses in the R&D tax credit laws; by transfer pricing adjustments; by tax effects of nondeductible compensation; by changes in accounting principles; or by changes in tax laws and regulations including possible U.S. or foreign changes to the taxation of earnings of our foreign subsidiaries, and the deductibility of expenses attributable to foreign income, or the foreign tax credit rules. Significant judgment is required to determine the recognition and measurement attribute prescribed in Financial Accounting Standards Board (FASB) Accounting Standards Codification 740,Income Taxes(“ASC 740”) (formerly referenced as FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes —an interpretation of FASB Statement No. 109”). ASC 740 applies to all income tax positions, including the potential recovery of previously paid taxes, which if settled unfavorably could adversely impact our provision for income taxes or additional paid-in capital. In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There can be no assurance that the outcomes from these continuous examinations will not have an adverse effect on our operating results and financial condition.
Natural disasters, terrorist attacks or acts of war may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our net sales, costs and expenses, and financial condition.
We have significant manufacturing and distribution facilities, particularly in the western U.S. (i.e. California) and in Germany. In particular, California has experienced a number of earthquakes, wildfires, flooding, landslides and other natural disasters in recent years. Occurrences of these types of events could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. Terrorist attacks have contributed to economic instability in the U.S. (such as those that occurred on September 11, 2001), and further acts of terrorism, bioterrorism, violence or war could affect the markets in which we operate, our business operations, our expectations and other forward-looking statements contained or incorporated in this document. Any of these events could have an adverse effect on our operating results and financial condition.
We may experience difficulties with obtaining components from sole- or limited-source suppliers, or manufacturing delays, either of which could adversely affect our results of operations.
Most raw materials, components and supplies that we purchase are available from many suppliers. However, certain items are purchased from sole or limited-source suppliers and a disruption of these sources could adversely affect our ability to ship products as needed. A prolonged inability to obtain certain materials or components would likely reduce product inventory, hinder sales and harm our reputation with customers. Worldwide demand for certain components may cause the cost of such components to rise or limit the availability of these components, which could have an adverse effect on our results of operations.
We manufacture products in our facilities in Germany, the Netherlands and the U.S. Any prolonged disruption to the operations at these facilities, whether due to labor unrest, supplier issues, damage to the physical plants or equipment or other reasons, could also adversely affect our results of operations.
If we fail to properly transition manufacturing currently performed at the ESA Biosciences facility to our manufacturing facilities in Germany and Sunnyvale, we may experience shipment delays, cost overruns, excess inventory and other problems, which may adversely impact our business and operating results.
In fiscal year 2011, we currently plan to transition manufacturing from the ESA Biosciences manufacturing facility in Massachusetts to our manufacturing facilities in Germany and Sunnyvale. If the transition does not go as expected, it could result in the following in addition to other potential issues, each of which could have an adverse effect on our business and operating results and our business reputation:
•  delay of shipments;
•  unexpected cost overruns; and
•  overstock of inventory as a result of building excessive buffer stock.
Credit risks associated with our customers may adversely affect our financial position or result of operations.

23


Because trade credit is extended to many of our customers, the current global economic condition may adversely affect our ability to collect on accounts receivable that are owed to us. In general, our customers are evaluated for their credit worthiness as part of our operating policy, and letters of credit are utilized to mitigate credit risks when possible. We believe we have adopted the appropriate operating policies to address the customer credit risk under a stable economic environment. Nevertheless, given the current global economic situation we could experience delays in collection on accounts receivable that are owed to us. As a result, this could adversely affect our financial position or result of operations.
Fluctuations in worldwide demand for analytical instrumentation could affect our operating results.
The demand for analytical instrumentation products can fluctuate depending upon capital expenditure cycles. Most companies consider our instrumentation products capital equipment and some customers may be unable to secure the necessary capital expenditure approvals due to general economic or customer specific conditions. Significant fluctuations in demand could harm our results of operations.

21


Fluctuations in our quarterly operating results may cause our stock price to decline.
A high proportion of our costs are fixed due in part to our significant sales and marketing, research and product development and manufacturing costs. Declines in revenue caused by fluctuations in currency rates, worldwide demand for analytical instrumentation or other factors could disproportionately affect our quarterly operating results, which may in turn cause our stock price to decline.
A significant portion of our cash position is maintained overseas.
Most of our short termshort-term debt is in the United States.U.S. While there is a substantial cash requirement in the U.S. to fund operations and capital expenditures, service debt obligations, finance potential acquisitions and continue authorized stock repurchases, a significant portion of our cash is maintained and generated from foreign operations. Our financial condition and results of operations could be adversely impacted if we are unable to maintain a sufficient level of cash flow in the U.S. to address these requirements through cash from U.S. operations, efficient and timely repatriation of cash from overseas and other sources obtained at an acceptable cost.
Our results of operations and financial condition will suffer if we do not introduce new products that are attractive to our customers on a timely basis.
Our products are highly technical in nature. As a result, many of our products must be developed months or even years in advance of the potential need by a customer. If we fail to introduce new products and enhancements as demand arises or in advance of the competition, our products are likely to become obsolete over time, which would harm operating results. Also, if the market is not receptive to our newly-developed products, our results of operations would be adversely impacted and we may be unable to recover the costs of research and product development and marketing associated with such products.
The analytical instrumentation market is highly competitive, and our inability to compete effectively in this market would adversely affect our results of operations and financial condition.
The analytical instrumentation market is highly competitive and we compete with many companies on a local and international level that are significantly larger than we are and have greater resources, including larger sales forces and technical staff. Competitors may introduce more effective and less costly products and, in doing so, may make it difficult for us to acquire and retain customers. If this occurs, our market share may decline and operating results could suffer.

24


We may experience difficulties with obtaining components from sole- or limited-source suppliers, or manufacturing delays, either of which could adversely affect our results of operations.
Most raw materials, components and supplies that we purchase are available from many suppliers. However, certain items are purchased from sole or limited-source suppliers and a disruption of these sources could adversely affect our ability to ship products as needed. A prolonged inability to obtain certain materials or components would likely reduce product inventory, hinder sales and harm our reputation with customers. Worldwide demand for certain components may cause the cost of such components to rise or limit the availability of these components, which could have an adverse effect on our results of operations.
We manufacture products in our facilities in Germany, the Netherlands and the United States. Any prolonged disruption to the operations at these facilities, whether due to labor unrest, supplier issues, damage to the physical plants or equipment or other reasons, could also adversely affect our results of operations.
Our executive officers and other key employees are critical to our business, they may not remain with us in the future and finding talented replacements may be difficult.
Our operations require managerial and technical expertise. Each of theour executive officers and key employees is employed “at will” and may leave our employment at any time. In addition, we operate in a variety of locations around the world where the demand for qualified personnel may be extremely high and is likely to remain so for the foreseeable future. As a result, competition for personnel can be intense and the turnover rate for qualified personnel may be high. The loss of any of our executive officers or key employees could cause us to incur increased operating expenses and divert senior management resources in searching for replacements. An inability to hire, train and retain sufficient numbers of qualified employees would seriously affect our ability to conduct our business. In April 2009, we hired a new President and Chief Executive Officer, Dr. Frank Witney, to succeed Lukas Braunschweiler who had served as our President and Chief Executive Officer since 2002. The success of our business will depend in part on the successful integration of Dr. Witney into our management team and the continued success of Dr. Witney and the rest of our management team in developing and executing our strategic plans.

22


We may be unable to protect our intellectual property rights and may face intellectual property infringement claims.
Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. We cannot be certain that:
  any of our pending patent applications or any future patent applications will result in issued patents;
 
  the scope of our patent protection will exclude competitors or provide competitive advantages to us;
 
  any of our patents will be held valid if subsequently challenged; or
 
  others will not claim rights in or ownership of the patents and other proprietary rights held by us.
Furthermore, we cannot be certain that others have not or will not develop similar products, duplicate any of our products or design around any patents issued, or that may be issued, in the future to us or to our licensors. Whether or not patents are issued to us or to our licensors, others may hold or receive patents which contain claims having a scope that covers products developed by us. We could incur substantial costs in defending any patent infringement suits, whether or not such suits have merit, or in asserting any patent rights, including those granted by third parties. In addition, we may be required to obtain licenses to patents or proprietary rights from third parties. There can be no assurance that such licenses will be available on acceptance terms, if at all.
Our issued U.S. patents, and corresponding foreign patents, expire at various dates ranging from 20092010 to 2029. When each of our patents expires, competitors may develop and sell products based on the same or similar technologies as those covered by the expired patent. We have invested in significant new patent applications, and we cannot be certain that any of these applications will result in an issued patent to enhance our intellectual property rights.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Repurchases
WeDuring the three months ended September 30, 2010, we repurchased shares of our common stock under a systematic program to manage the dilution created by shares issued under employee stock plans and for other purposes. This program authorizes repurchases in the open market or in private transactions. We started a series of repurchase programs in fiscal 1989, with the boardBoard of directorsDirectors most recently authorizing in October 2008 future repurchases of an additional 1.0 million1,000,000 shares of common stock in October 2008 as well as authorizing the repurchase of additional shares of common stock equal to the number of shares of common stockshares issued pursuant to our employee stock plans.

25


The following table indicates common shares repurchased and additional shares added to the repurchase program during the three months ended September 30, 2009:2010:
ISSUER PURCHASES OF EQUITY SECURITIES
                     
          Total      
          Number of     Maximum
          Shares     Number of
          Purchased Additional Shares that
  Total Avg. as Part of Shares May Yet Be
  Number Price Publicly Authorized Purchased
  of Shares Paid Announced for Under the
Period Purchased per Share Program Purchase (1) Program (2)
July 1 to July 31, 2009        7,814,025      1,141,058 
August 1 to August 31, 2009  101,586  $58.46   7,915,611   29,611   1,069,083 
September 1 to September 30, 2009  86,667  $60.40   8,002,278   46,630   1,029,046 
                     
Total  188,253  $59.36   8,002,278   76,241   1,029,046 
                     
          Total      
          Number of     Maximum
          Shares     Number of
          Purchased Additional Shares that
  Total Avg. as Part of Shares May Yet Be
  Number Price Publicly Authorized Purchased
  of Shares Paid Announced for Under the
Period Purchased per Share Program Purchase (1) Program (2)
July 1 to July 31, 2010        8,589,669      817,844 
August 1 to August 31, 2010  106,207  $73.49   8,695,876   18,894   730,531 
September 1 to September 30, 2010  80,976  $75.92   8,776,852   32,905   682,460 
                     
Total  187,183  $74.54   8,776,852   51,799   682,460 
 
(1) The number of shares represents the number of shares issued pursuant to employee stock plans that are authorized for purchase.
 
(2) The number of shares includes (i) 1.0 million shares of common stock approved for repurchases in October 2008, plus (ii) that

23


number of shares of common stock equal to the number of shares issued pursuant to employee stock plans subsequent to October 2008 minus the number of shares repurchased, plus (iii) the number of shares remaining from the repurchase authorization in August 2006.
DIVIDENDSDividends
As of September 30, 2009,2010, we had paid no cash dividends on our common stock and we do not anticipate doing so in the foreseeable future.

2426


EXHIBIT INDEX
Item 6. EXHIBITS
       
Exhibit    
Number Description Reference
3.1 Restated Certificate of Incorporation, filed December 12, 1988  (1)
       
3.2 Certificate of Amendment of Restated Certificate of Incorporation, filed December 1, 1999 (Exhibit 3.2)  (11)
       
3.3 Amended and Restated Bylaws, dated August 6, 2008 (Exhibit 99.1)  (4)
       
*10.1 Medical Care Reimbursement Plan as amended October 30, 2007 (Exhibit 10.1)  (7)
       
10.2 Credit Agreement dated November 13, 2000 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.15)  (3)
       
10.3 First amendment to Credit Agreement dated November 13, 2000 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.17)  (5)
       
*10.4 Dionex Corporation 2004 Equity Incentive Plan, as amended October 2007 (Exhibit 10.1)  (12)
       
*10.5 Form of Stock Option Agreement for non-employee directors (Exhibit 10.5)  (13)
       
*10.6 Form of Stock Option Agreement for other than non-employee directors (Exhibit 10.6)  (13)
       
*10.7 Form of Stock Unit Award Agreement for non-employee directors (Exhibit 10.2)  (12)
       
*10.8 Form of International Stock Option Agreement (Exhibit 10.8)  (7)
       
*10.9 Employee Stock Participation Plan (Exhibit 10.13)  (6)
       
10.10 Second amendment to Credit Agreement dated November 13, 2000 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.1)  (8)
       
*10.11 Change in Control Severance Benefit Plan, as amended October 26, 2009 (Exhibit 99.1)  (2)
       
10.12 Third amendment to Credit Agreement dated December 1, 2006 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.8)  (10)
       
*10.13 Form of Stock Unit Award Agreement for U.S. employees (Exhibit 10.9)  (9)
       
*10.14 Form of Stock Unit Award Agreement for International employees (Exhibit 10.10)  (9)
       
*10.15 Form of Indemnification Agreement (Exhibit 10.1)  (14)
       
*10.16 Management Incentive Bonus Plan dated August 4, 2009 (Exhibit 99.1)  (15)
       
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
       
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
       
32.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
       
32.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
EXHIBIT INDEX
       
Exhibit    
Number Description Reference
3.1 Restated Certificate of Incorporation, filed December 12, 1988  (1)
       
3.2 Certificate of Amendment of Restated Certificate of Incorporation, filed December 1, 1999 (Exhibit 3.2)  (8)
       
3.3 Amended and Restated Bylaws, August 6, 2008 (Exhibit 99.1)  (12)
       
10.1* Medical Care Reimbursement Plan as amended October 30, 2007 (Exhibit 10.1)  (9)
       
10.2 Credit Agreement dated December 23, 2009 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.2)  (4)
       
10.3* Management Incentive Bonus Plan dated August 6, 2009 (Exhibit 99.1)  (6)
       
10.4* Dionex Corporation 2004 Equity Incentive Plan, as amended October 2007 (Exhibit 10.1)  (10)
       
10.5* Form of Stock Option Agreement for non-employee directors (Exhibit 10.5)  (11)
       
10.6* Form of Stock Option Agreement for other than non-employee directors (Exhibit 10.6)  (11)
       
10.7* Form of Stock Unit Award Agreement (Exhibit 10.2)  (10)
       
10.8* Form of International Stock Option Agreement (Exhibit 10.8)  (9)
       
10.9* Form of Stock Unit Award Agreement for U.S. employees  (2)
       
10.10* Form of Stock Unit Award Agreement for International employees  (2)
       
10.11* Employee Stock Participation Plan (Exhibit 10.13)  (5)
       
10.12* Form of Performance Stock Unit Grant Notice  (3)
       
10.13* Change in Control Severance Benefit Plan as amended April 26, 2010  (2)
       
10.14* Summary of Compensation Arrangements with named executive officers  (7)
       
10.15* Form of Indemnification Agreement (Exhibit 10.1)  (13)
       
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
       
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
       
32.1† Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
       
32.2† Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
 
101.INS XBRL Instance Document    
 
101.SCH XBRL Taxonomy Extension Schema Document    
 
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document    
 
101.LAB XBRL Taxonomy Extension Label Linkbase Document    
 
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document    
 
(1) Incorporated by reference to the correspondingindicated exhibit in our Annual Report on Form 10-K10-Q filed September 20, 1989. (file no. 000-11250).
 
(2) Incorporated by reference to the correspondingindicated exhibit in our Quarterly Report on Form 8-K filed October 30, 2009.April 28, 2010.
 
(3) Incorporated by reference to the indicated exhibit in our Quarterly Report on Form 10-Q10-K filed February 14, 2001. (file no. 000-11250).August 27, 2010.
 
(4) Incorporated by reference to the indicated Exhibitexhibit in our Form 8-K10-Q filed August 11, 2008.February 9, 2010.
 
(5) Incorporated by reference to the indicated Exhibitexhibit in our Annual Report on Form 10-K filed September 24, 2003. (file no. 000-11250).10, 2004.
 
(6) Incorporated by reference to the indicated exhibit in our Annual Report on Form 10-K8-K filed SeptemberAugust 10, 2004.2009.
 
(7)Incorporated by reference to the indicated exhibit in our Form 8-K filed August 9, 2010 and August 16, 2010.
(8)Incorporated by reference to the indicated exhibit in our Form 10-K filed August 29, 2007.
(9) Incorporated by reference to the indicated exhibit in our Form 10-Q filed November 9, 2007.
 
(8)Incorporated by reference to the indicated exhibit in our current Report on Form 8-K filed December 22, 2004.
(9)Incorporated by reference to the indicated exhibit in our Annual Report on Form 10-K filed August 29, 2008.
(10)Incorporated by reference to the indicated exhibit in our Quarterly Report on Form 10-Q filed February 9, 2007.
(11)Incorporated by reference to the indicated exhibit in our Form 10-K filed August 29, 2007.

25


(12) Incorporated by reference to the indicated exhibit in our Form 8-K filed October 15, 2007.
 
(13)(11) Incorporated by reference to the indicated exhibit in our Form 10-Q filed February 8, 2008.
 
(14)(12)Incorporated by reference to the indicated exhibit in our Form 8-K filed August 11, 2008.
(13) Incorporated by reference to the indicated exhibit in our Form 8-K filed November 3, 2008.
 
(15)Incorporated by reference to the indicated exhibit in our Form 8-K filed August 10, 2009.
* Management contract or compensatory plan or agreement.arrangement.
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

2627


SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
DIONEX CORPORATION
(Registrant)
     



Date: November 6, 2009
DIONEX CORPORATION
(Registrant)


8, 2010
 
 By: /s/ Craig A. McCollam  
  By:/s/ Craig A. McCollam
Craig A. McCollam
  
  Executive Vice President and Chief Financial Officer (Signing
(Signing as Principal Financial and Accounting
Officer, and as Authorized Signatory of Registrant)  
 Registrant)

2728


EXHIBIT INDEX
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
32.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
32.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document

2829